Establishment of An Automated Digital Prion Infectivity Cell Assay and PrP-HPFRET Based High-throughput siRNA Screening Platform by Li, Bei
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Establishment of An Automated Digital Prion Infectivity Cell Assay and
PrP-HPFRET Based High-throughput siRNA Screening Platform
Li, Bei
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-136312
Originally published at:
Li, Bei. Establishment of An Automated Digital Prion Infectivity Cell Assay and PrP-HPFRET Based
High-throughput siRNA Screening Platform. 2016, University of Zurich, Faculty of Science.
 
 
Establishment of An Automated Digital Prion 
Infectivity Cell Assay and PrP-HPFRET Based 
High-throughput siRNA Screening Platform 
 
 
 
 
 
Dissertation 
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
von 
Bei Li 
aus 
China, PRC 
 
 
 
Promotionskomitee 
Prof. Dr. Adriano Aguzzi (Vorsitz) 
Prof. Dr. Charles Weissmann 
Prof. Dr. Ben Schuler 
 
 
Zürich, 2016 
 TABLE OF CONTENT 
 
2 
 
Table of Contents 
1 SUMMARY ..................................................................................................................... 5 
2 ZUSAMMENFASSUNG .................................................................................................. 7 
3 ABBREVIATIONS .......................................................................................................... 9 
4 INTRODUCTION ...........................................................................................................11 
4.1 Prion diseases .............................................................................................................11 
4.1.1 Animal prion diseases ..........................................................................................11 
4.1.2 Human prion diseases ..........................................................................................12 
4.2 The cellular prion protein .............................................................................................12 
4.2.1 PrPC expression pattern .......................................................................................12 
4.2.2 Biosynthesis of PrPC .............................................................................................12 
4.2.3 Structure of PrPC ..................................................................................................13 
4.2.4 Physiological function of PrPC ...............................................................................13 
4.3 Models of prion replication ...........................................................................................14 
4.4 Prion pathogenesis ......................................................................................................15 
4.5 Prionoid in PMDs.........................................................................................................16 
4.6 Strategies for potential therapeutic targets of prion diseases .......................................18 
4.7 Aims of the thesis ........................................................................................................19 
5 RESULTS PART I: ESTABLISHMENT OF AN AUTOMATED DIGITAL PRION 
INFECTIVITY CELL ASSAY (DPICA) ...........................................................................21 
5.1 Introduction .................................................................................................................21 
5.2 Specific aims of the project ..........................................................................................22 
5.3 Development of HPFRET assays for detecting prion proteins .....................................22 
5.3.1 Establishment of PrPC-HPFRET ...........................................................................23 
5.3.2 Establishment of PrPSc-HPFRET ..........................................................................25 
5.4 Establishment of digital prion infectivity cell assay (DPICA) .........................................29 
5.4.1 Overview of DPICA scheme .................................................................................29 
5.4.2 Numerical treatment of DPICA data ......................................................................30 
5.4.3 Automation of DPICA ...........................................................................................31 
5.4.4 Validation of DPICA ..............................................................................................31 
5.4.5 Comparison of the DPICA, SCEPA and mouse bioassay .....................................34 
5.4.6 Application of DPICA to assessment of prion decontamination .............................35 
5.4.7 Application of DPICA to assessment of prion infectivity in various mouse brain 
regions .................................................................................................................37 
5.5 Discussion ...................................................................................................................38 
5.6 Outlook ........................................................................................................................39 
5.7 Material and Methods ..................................................................................................39 
 TABLE OF CONTENT 
 
3 
 
5.7.1 PrPC-HPFRET ......................................................................................................39 
5.7.2 PrPSc-HPFRET .....................................................................................................40 
5.7.3 FRET calculation ..................................................................................................41 
5.7.4 Preparation of FRET antibody pairs ......................................................................41 
5.7.5 Mouse prion susceptible cell line and prion inoculum ...........................................42 
5.7.6 DPICA protocol .....................................................................................................42 
5.7.7 Automated liquid handling platform .......................................................................45 
5.7.8 Sample preparation from various mouse brain regions .........................................45 
5.7.9 Scrapie cell assay in end point format ..................................................................46 
5.7.10 Mouse bioassay ...................................................................................................46 
5.7.11 Preparation of prion decontaminated samples ......................................................46 
6 RESULTS PART II: ESTABLISHMENT OF AN AUTOMATED PRP-HPFRET BASED 
HIGH-THROUGHPUT SIRNA SCREENING PLATFORM .............................................49 
6.1 Introduction .................................................................................................................49 
6.1.1 RNA profile change upon prion infection ...............................................................49 
6.1.2 Small RNAs based targets identification for prion disease ....................................49 
6.1.3 HTS applications for discovering prion therapeutic target .....................................50 
6.2 Specific aims of the project ..........................................................................................52 
6.3 Application of PrPC-HPFRET and PrPSc-HPFRET for assessing RNAi-mediated gene 
silencing in neuronal cells ............................................................................................52 
6.4 Establishment of an automated siRNA HTS platform ..................................................53 
6.5 HTS of 3127 murine siRNAs targeting 780 genes involved in endocytosis pathways ..55 
6.5.1 Screen of an arrayed murine siRNAs to identify genes regulating endogenous PrPC 
expression ............................................................................................................55 
6.5.2 Screen raw data analysis......................................................................................55 
6.5.3 Silencing Tfr1 efficiently downregulated PrPC and blocked PrPSc replication in 
neuronal cells .......................................................................................................58 
6.5.4 Tfr1-siRNA treatment reduced the Prnp mRNA level ............................................60 
6.5.5 Genome-wide transcriptome analysis of Tfr1-siRNA treated CAD5 by RNAseq ...62 
6.5.6 Regulation of PrPC expression by iron treatment in cell culture .............................69 
6.5.7 Inhibition of PrPSc replication by iron treatment in cell culture ...............................71 
6.5.8 Regulation of PrPC expression by iron treatment in mouse model ........................73 
6.6 Discussion ...................................................................................................................74 
6.7 Outlook ........................................................................................................................75 
6.8 Material and Methods ..................................................................................................75 
6.8.1 Chemicals and tissue homogenate .......................................................................75 
6.8.2 Mouse prion susceptible neuronal cell line ...........................................................75 
 TABLE OF CONTENT 
 
4 
 
6.8.3 Murine siRNA screen ............................................................................................76 
6.8.4 Screen data analysis ............................................................................................79 
6.8.5 RNA sequencing ..................................................................................................79 
6.8.6 qRT-PCR. .............................................................................................................80 
6.8.7 Western blot analysis ...........................................................................................80 
6.8.8 Iron treatment in neuronal cells.............................................................................81 
6.8.9 Iron treatment before or after prion infection in neuronal cells ..............................81 
6.8.10 Iron treatment in mice ...........................................................................................82 
6.8.11 Statistical analysis. ...............................................................................................82 
7 REFERENCES ..............................................................................................................83 
8 ACKNOWLEDGMENTS ................................................................................................95 
9 CURRICULUM VITAE ...................................................................................................97 
Chapter 1 SUMMARY 
 
5 
 
1 Summary 
Prion diseases are a group of transmissible fatal neurodegenerative diseases, including the 
Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI), Gerstmann-Sträussler-
Scheinker syndrome (GSS) and Kuru in humans, bovine spongiform encephalopathy (BSE) 
in cattle, scrapie in sheep and goat, chronic wasting disease (CWD) in deer, moose and elk.  
The disease causing agents consists of aggregated PrPSc, a misfolded isoform of the host 
cellular prion protein (PrPC).  In a prion replication process, PrPSc acts as a propagon that is 
capable of seeding a self-perpetuating reaction to convert more PrPC to PrPSc. The number 
of monomers in each prion propagon is variable; therefore, prion infectivity titers cannot be 
predicted by merely measuring PrPSc but necessitate bioassays, which require inoculation of 
serially diluted prions into susceptible animals. The conventional animal bioassay is time-
consuming, cost-ineffective and ethically problematic; hence, it is imperative to establish a 
rapid, economic and sensitive method to determine prion infectivity titers. 
The PrPC expression level is the main determinant of prion pathogenesis. Prnp-/- 
homozygous mice are resistant to prion infection. Reduction of PrPC by 50% (Prnp+/- 
heterozygous mice) significantly prolongs the incubation time of prion disease, whereas 
overexpression of PrPC remarkably shortens disease progression. However, the intrinsic 
molecular mechanisms underlying prion protein expression and replication are currently far 
less understood. This is mainly because the conventional detection methods for prion 
proteins have inherent limitations in applicability to high-throughput research, leading to the 
dearth of high-throughput technology that can be used to characterize the fundamental 
molecular mechanisms. 
In the first part of the thesis, I developed homogeneous-phase fluorescence resonance 
energy transfer (HPFRET) assays for detecting prion proteins, designated as PrPC-HPFRET 
and PrPSc-HPFRET. Next, I established an automated digital prion infectivity cell assay 
(DPICA), which requires minimal manipulation of infectious materials. The DPICA readout is 
based on highly parallel cell-based PrPSc-HPFRET bioassays: 100 prion susceptible 
cells/well were seeded in 384-well plates and exposed to prions. After ten days of culture, 
lysis buffer containing proteinase K, denaturing buffer, neutralizing buffer and a pair of 
fluorescently labelled anti-PrP antibodies were sequentially added. PrPSc-HPFRET signal in 
each well was detected by a RT-FRET reader. The results were analysed with sophisticated 
numerical methods intended to filter noise from the binomially distributed biological data. The 
DPICA detected 106.5 propagons/g and 105.4 propagons/g in two distinct mouse prion strains, 
RML6 and Me7, thus demonstrating the number of propagons in the samples. This bioassay 
can be applied to a fully automated platform, and is therefore suitable for high-throughput 
screening (HTS) applications. 
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In the second part of the thesis, I utilized the PrPC-HPFRET and PrPSc-HPFRET to assess 
RNAi-mediated gene silencing in neuronal cells, and established an automated PrP-HPFRET 
based high-throughput siRNA screening platform to identify genes affecting cellular prion 
protein expression. Next, I screened an arrayed murine siRNA library including 3153 siRNAs 
targeting 780 genes that are involved in endocytosis pathways. I identified the transferrin 
receptor 1 (Tfr1 or Tfrc) as an interesting hit, such that Tfr1-siRNA treatment efficiently 
downregulated PrPC expression and blocked PrPSc replication in neuronal cells. By qPCR 
analysis, I found that Prnp mRNA levels in Tfr1-siRNA transfected wide-type neuronal cells 
were also significantly reduced, suggested that silencing Tfr1 repressed endogenous PrPC 
expression at the transcriptional/post-transcriptional level. Further, genome-wide 
transcriptome analysis of Tfr1-siRNA treated CAD5 cells by RNAseq confirmed the qPCR 
results and showed that 99 genes were significantly changed with >4-fold-change, p-value < 
1e-5, in which 48 genes were down-regulated (Tfr1 was top7 and Prnp was top11 down 
regulated) and 51 genes were upregulated. Finally, I modulated the Tfr1 level in a cell culture 
model and mouse model by iron supplement or chelator treatment, and found that PrPC 
expression can be significantly altered. These results imply that Tfr1 may represent a 
potential therapeutic target for prion diseases. The PrP-HPFRET based high-throughput 
siRNA screening platform will provide a powerful tool for discovering unknown molecular 
mechanisms and even novel approaches for prion therapy. 
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2 Zusammenfassung 
 
Prionenerkrankungen bilden eine Gruppe von übertragbaren, tödlich verlaufenden 
neurodegenerativen Erkrankungen. Bei Menschen gehören Creutzfeldt-Jakob-Krankheit, 
Fatale Familiäre Insomnie, Gerstmann-Sträussler-Scheinker-Syndrom und die Kuru 
Krankheit dazu. Zu den Prionenerkrankungen bei Tieren zählen die Bovine Spongiforme 
Encephalopathie bei Rindern (BSE), die Schaberkrankheit („Scrapie") bei Schafen und 
Ziegen und die Chronic Wasting Disease» (CWD) der Hirsche und Elche. 
Das die Krankheit auslösende Agens besteht aus aggregiertem PrPSc, einer fehlgefalteten 
Isoform des körpereigenen Prion Proteins (PrPC). PrPSc wirkt bei dieser Erkrankung als 
Propagon, das in einem Replikationsprozess dazu befähigt ist PrPC in PrPSc umzuwandeln. 
Die Zahl von Monomeren in jedem Prionpropagon ist variabel, deshalb lässt sich der 
Prionentiter nicht von der detektierten Menge von PrPSc ableiten, sondern bedarf eines 
Bioassays, der durch Inokulationsexperimente in Tiere mit verschiedenen Verdünnungen der 
Prionen bestimmt werden kann. Der klassische Tier-Bioassay ist ineffizient, kostspielig und 
ethisch problematisch, daher ist eine schnellere, preisgünstige und sensitive Methodik 
zwingend erforderlich. 
Bei der Pathogenese von Prionenerkrankungen spielt die PrPC Expressionsmenge eine 
entscheidende Rolle, wobei Prnp-/- homozygote Mäuse infektionsresistent sind bzw. Mäuse 
mit einer 50% igen Verminderung von PrPC (Prnp+/- heterozygous mice) eine signifikante 
Verlängerung der Inkubationszeit von Prionenerkrankungen zeigen. Im Gegensatz dazu führt 
eine Überexpression von PrPC zu einer deutlich kürzeren Erkrankungsdauer. Allerdings sind 
die Mechanismen, die zur Prionenreplikation führen, noch nicht vollständig geklärt. 
Das ergibt sich vor allem dadurch, dass die herkömmlichen Nachweismethoden durch das 
Fehlen von High throughput Technologien limitiert sind, die für die Aufklärung dieser 
Fragestellung eine entscheidende Rolle spielen. 
Im ersten Teil meiner Doktorarbeit, um Prionenproteine zu detektieren, habe ich einen 
Försters Fluorescenz Resonanz Emissionstransfer (HPFRET) Assay, als PrPC-HPFRET and 
PrPSc-HPFRET bezeichnet, verwendet. Als Nächstes habe ich einen automatisierten, 
digitalen Prionen Infektivitäts Assay (DPICA), der minimale Manipulation von infektiösem 
Material benötigt. Der Readout basiert auf einem parallel-angeordneten zellbasierten PrPSc-
HPFRET Bioassay. 100 Zellen pro Well wurden ausplattiert und mit Prionen infiziert. Nach 
10 Tagen Zellkultivierung wurden nacheinander Lysepuffer, welcher Proteinase K enthält, 
Denaturierungspuffer, Neutralisationspuffer und ein Fluoreszenz gelabeltes Antikörperpaar 
hinzugegeben. 
Das PrPSc-HPFRET Signal wird mittels eines RT-FRET detektiert. Die Ergebnisse werden als 
numerische Methoden bewertet, welche Rauschen von binomial verteilten biologischen 
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Daten filtrieren. Der DPICA-Assay detektierte 106.5 Propagone/g und 105.4 Propagone/g in 
den zwei verschiedenen Mausprionenstämmen RML6 und Me7. Dies entspricht der Zahl der 
Propagone innerhalb der Proben. Dieser Bioassay lässt sich komplett automatisiert 
durchführen und ist daher als High throughput screen (HTS) geeignet. 
Im zweiten Teil meiner Arbeit habe ich den PrPC-HPFRET und PrPSc-HPFRET genutzt, um 
RNAi-mediiertes „gene silencing“ in neuronalen Zellen zu bestimmen. Des Weiteren habe ich 
einen automatisierten PrP-HPFRET Assay etabliert, basierend auf dem high-throughput 
siRNA screen, um Gene zu identifizieren, die die Expression des zellulären Prion Proteins 
beeinflussen. Anschliessend habe ich einen Array von Maus siRNA gescreened , welcher 
3153 siRNAs umfasst, die 780 Gene betreffen, welche den Endozytose Signalweg 
beeinflussen. Dabei habe ich den Transferrin Rezeptor 1 (Tfr1 oder Tfrc) als möglichen 
Kandidaten detektiert, bei dem die siRNA Behandlung zu einer Runterregulation der PrPC 
Expression und somit Verhinderung der PrPSc Replikation in neuronalen Zellen geführt hat. 
Mittels quantitativer PCR Analyse, konnte ich zeigen, dass die mRNA Level von Prnp in Tfr1-
siRNA transfizierten neuronalen Zellen also signifikant vermindert waren, was darauf 
hinweist, dass silencing von Tfr1 die endogene PrPC Expression auf transkriptionaler/ 
posttranskriptionaler Ebene unterdrückt. Weiterhin konnten die Genom basierten 
Transkriptom Analysen der -siRNA behandelten CAD5 Zellen mittels RNAseq die PCR 
Ergebnisse untermauert und gezeigt werden, dass 99 Gene eine signifikante Änderung, > als 
4 fach, und p-Wert < 1e-5, unter denen 48 Gene runterreguliert waren (mit Tfr1 als 7. und 
Prnp als 11. runterreguliert) und 51 genes waren hochreguliert. Zu guter letzt habe ich das 
Tfr1 level in einem Zellkultur Modell durch Eisen Zusatz oder Chelator Behandlung moduliert. 
Dabei zeigte sich, dass die PrPC Expression sich signifikant änderte. Diese Ergebnisse 
weisen darauf hin, dass Tfr1 ein potentielles therapeutisches Target für 
Prionenerkrankungen darstellen könnte. Der PrP-HPFRET basierte high-throughput siRNA 
screen stellt sich als ein wichtiges Werkzeug für die Aufdeckung unbekannter molekularer 
Mechanismen und neuen Ansätzen der Prionen Therapie dar. 
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3 Abbreviations 
AA      amino acid 
Aβ   amyloid-β 
AD   Alzheimer’s diseases 
ALS   amyotrophic lateral sclerosis 
APP   amyloid precursor protein 
BH   brain homogenate 
BSA    bovine serum albumin 
BSE    bovine spongiform encephalopathy 
CJD    Creutzfeldt-Jakob disease 
CNS    central nervous system 
CWD    chronic wasting disease  
DPICA   digital prion infectivity cell assay 
dpi      days post infection 
ER    endoplasmic reticulum 
fCJD    familial Creutzfeldt-Jakob disease 
FFI    familial fatal insomnia 
FTD   frontotemporal dementia 
GPI   glycosylphosphatidylinositol 
GSS   Gerstmann-Sträussler-Scheinker syndrome 
HPFRET   homogeneous-phase fluorescence resonance energy transfer 
KD   kilo Dalton 
LD50   median lethal dose 
MSA   multiple system atrophy 
NBH    non-infectious brain homogenate 
PD    Parkinson’s diseases  
PK    proteinase K 
POM 1-19   set of 19 anti-PrP monoclonal antibodies 
Prnp    murine prion gene 
PRNP    human prion gene 
PrP    prion protein 
PrPC    cellular prion protein 
PrPSc   scrapie-associated prion protein 
RML6    Rocky Mountain laboratory strain, passage 6 
SEM   standard error of the mean 
SD      standard deviation 
sCJD    sporadic Creutzfeldt-Jakob disease 
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SCEPA   scrapie cell assay in end point format 
TCID50   tissue culture infectivity 50% dose 
Tga20   transgenic mice overexpressing PrPC 
TSE   transmissible spongiform encephalopathies 
vCJD    variant Creutzfeldt-Jakob disease 
WT    wild-type 
KO   knockout 
263K    hamster adapted scrapie prions 
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4 Introduction 
4.1 Prion diseases 
Prion diseases also known as transmissible spongiform encephalopathies (TSEs), are a 
group of fatal neurodegenerative disorders marked by neuronal loss, vacuolization, gliosis, 
and spongiform changes in the brain (Aguzzi, Nuvolone et al. 2013). In animals, prion 
diseases include scrapie in sheep and goats (Cuille J and Chelle PL 1939), chronic wasting 
disease (CWD) in deer, moose and elk (Williams and Young 1980), and bovine spongiform 
encephalopathy (BSE) in cattle (Hope J, Ritchie L et al. 1989). In humans, prion diseases 
include Creutzfeldt-Jacob diseases (CJD) (Gibbs, Gajdusek et al. 1968), fatal familial 
insomnia (FFI) (Medori, Tritschler et al. 1992), Gerstmann-Sträussler-Scheinker syndrome 
(GSS) (Gajdusek 1977) and Kuru (Gajdusek, Gibbs et al. 1966). 
The disease causing agent consists of PrPSc, which is an isoform of the host-encoded 
cellular prion protein PrPC. PrPSc that acts as a propagon, which is capable of seeding a self-
perpetuating reaction to convert PrPC to itself within a bioassay system (Aguzzi, Nuvolone et 
al. 2013). This process is termed as prion replication. The cellular prion protein PrPC is 
encoded by the PRNP gene (Basler, Oesch et al. 1986). Its expression is indispensable for 
prion replication and prion-induced neurodegeneration (Bueler, Aguzzi et al. 1993). However, 
the intrinsic molecular mechanisms of prion replication and subsequent neurodegeneration 
are still largely unknown (Weissmann 2005). 
 
4.1.1 Animal prion diseases 
The first case of scrapie was reported in Spanish merino sheep in 1732 (Liberski 2012). The 
name “scrapie” was derived from the observation that diseased sheep scrape themselves 
against objects. Scrapie was proven to represent a transmissible disease among sheep and 
goats (Cuille J and Chelle PL 1939, Gordon 1946). The first case of CWD was reported in 
Colorado, then spread around North America and to South Korea (Sigurdson and Aguzzi 
2007). In 1986, the first case of BSE, later known by the popular name "mad-cow disease", 
was described in in the UK (Wells, Scott et al. 1987). Subsequently, the disease rapidly 
developed into a major epidemic in European countries. In the last 30 years, over 280,000 
animals were affected by prion diseases (Aguzzi and Calella 2009). The use of prion-infected 
bone and meat in cattle food was considered a major source of BSE (Weissmann and Aguzzi 
1997). Other possible routes of infection described in animals include the milk of sheep 
suffering from scrapie or mastitis (Ligios, Sigurdson et al. 2005), the urine of mice affected by 
scrapie and nephritis (Seeger, Heikenwalder et al. 2005), and the saliva and blood of deer 
with CWD (Mathiason, Powers et al. 2006). It is mandatory to implement stringent control 
measures to eliminate the  risk of infectious materials in animal feed, and thereby reduce the 
incidence of prion disease (Hope 2013) 
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4.1.2 Human prion diseases 
Five human prion diseases have been recognized so far: Creutzfeldt-Jakob disease (CJD), 
variant Creutzfeldt-Jakob disease (vCJD), fatal familial insomnia (FFI), Gerstmann-
Sträussler-Scheinker syndrome (GSS) and Kuru. Sporadic CJD comprises 85% of human 
prion diseases, 10 – 15% cases are familial (fCJD) and 1% cases are iatrogenic. Human 
prion diseases can be subdivided into inherited, sporadic and infectious forms, based on 
their clinical presenation, genetic and neuropathological features (Aguzzi and Calella 2009).  
The inherited prion diseases fCJD, FFI and GSS are associated with an autosomal dominant 
mutation in PRNP (Johnson and Gibbs 1998). In general, fCJD is associated with point 
mutations, insertions or deletions in the PRNP gene, and presents at an earlier age, with a 
more prolonged clinical course than sporadic CJD (Johnson and Gibbs 1998, Aguzzi and 
Calella 2009). FFI is characterized by a mutation in PRNP that replaces the amino acid 
asparagine (N) with methionine (M) at codon 129 and aspartic acid (D) at codon 178 
(Gambetti, Parchi et al. 1995). GSS is inherited in an autosomal dominant manner with 
mutations in PRNP mostly at codons 102 and 198, and characterized histopathologically by 
multicentric amyloid plaques positive for PrP (Collins, McLean et al. 2001). 
 
4.2 The cellular prion protein 
4.2.1 PrPC expression pattern 
The host cellular prion protein (PrPC) is highly conserved in mammals, implying important 
functions of PrPC. Although PrP-deficient (Prnp-/-) mice are generally believed to perform well, 
an evolutionary pressure must exist to counterbalance the susceptibility of Prnp-expressing 
individuals to prion disease (Mead, Stumpf et al. 2003). PrPC is highly expressed in the 
central nervous system (CNS), and also in several peripheral tissues and cells including 
heart, skeletal muscle, kidney and lymphocytes (Dodelet and Cashman 1998, Ford, Burton et 
al. 2002). Inflammatory conditions can trigger ectopic PrPC expression and prion replication 
competence in organs that normally express low amounts of PrPC (Heikenwalder, Zeller et al. 
2005). In the CNS, PrPC is ubiquitously expressed with the highest levels found in neuronal 
and glial cells (Aguzzi, Baumann et al. 2008). 
 
4.2.2 Biosynthesis of PrPC 
Murine PrP gene (Prnp) has three exons. Exon 3 contains an open reading frame (ORF) and 
a 3' untranslated region (3' UTR), whereas Human PrP gene (PRNP) has two known exons 
and one putative exon. So far, the equivalent of murine exon 2 has not been found in human 
RNA transcripts. The murine PrPC protein is 254 amino acids (aa) in length, which includes a 
22 amino acid signal peptide, five octapeptide repeats, one disulphide bond (S–S) between 
cysteine residues 178 and 213, and two potential sites for N-linked glycosylation (CHO) at 
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residues 180 and 196. A glycosylphosphatidylinositol (GPI) anchor is attached to the C-
terminus of PrP at residues 231 to 254. The human PrPC protein consists of 245 amino acids 
and has the same structural features as murine PrPC protein. PrPC is synthesized in the 
endoplasmic reticulum (ER) (Stahl, Borchelt et al. 1987). The key signal peptide for directing 
PrPC into the ER is located in amino acids 1 – 22, and is subsequently cleaved off. Two 
glycans chains are attached at asparagine 181 and 197, and a disulphide bridge is formed 
between cysteine 197 and 214. After removing the  C-terminal peptide, a GPI anchor is 
attached (Harris 2003). PrPC is folded and transported to the Golgi, where additional 
modifications are made in glycans and the GPI anchor, before being sent to the cell surface. 
Finally, mature PrPC at the cell surface is endocytosed into internal endosomal 
compartments, where it can either be recycled into the cell membrane or sent to lysosomes 
for degradation (Chakrabarti, Ashok et al. 2009). In cell culture, most PrPC is degraded 
through the lysosome or proteasome pathway (Caughey and Lansbury 2003). Roughly less 
than one third of PrPC is shed into the medium (Borchelt, Scott et al. 1990). 
 
4.2.3 Structure of PrPC 
PrPC proteins in mammals have a similar three-dimensional structure that consists of two 
distinct domains: a C-terminal structured globular domain (aa 126 – 231) and an N-terminal 
unstructured flexible tail (aa 23 – 125) (Aguzzi and Calella 2009). The structured C-terminal 
globular domain consists of double-stranded antiparallel β-pleated sheets (aa 128-131 and 
161 – 164), three α-helices (aa 144 – 154, 173 – 194 and 200 – 228) and a disulphide bond 
linking helices two and three. (Riek, Hornemann et al. 1996). The unstructured N-terminal 
flexible tail contains a segment of five repeats so called “octarepeat” region, which is flanked 
by two positively charged clusters CC1 (aa 23 –27) and CC2 (aa 95 – 110). The octarepeat 
region may be involved in copper binding and inherited prion diseases with insertion of 
mutations (Aguzzi and Calella 2009). The two domains are linked by a highly conserved 
hydrophobic core (aa 111 – 134). 
 
4.2.4 Physiological function of PrPC 
Several physiological roles of PrPC are recognized including myelin homeostasis, circadian 
rhythm, memory formation, and immunological processes such as phagocytosis, and the 
self-renewal of hematopoietic stem cells (Steele, Lindquist et al. 2007). Many of these 
functions are still controversial because of the mixed background of Prnp-/- mice and the 
problem of flanking genes (Nuvolone, Kana et al. 2013). Our lab has shown that neuronal 
ablation of PrPC or the prevention of PrPC cleavage produces chronic demyelinating 
polyneuropathy in Prnp-/- mice of various genetic backgrounds (Bremer, Baumann et al. 2010) 
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and recent studies have demonstrated that the PrPC promotes myelin homeostasis through 
FT-mediated Gpr126 agonism in Schwann cells (Küffer et al., 2016 in press). 
 
4.3 Models of prion replication 
The protein-only hypothesis proposes that the nature of the infectious entity responsible for 
triggering of any prion disease consists mainly of PrPSc, which is an abnormally-folded, 
protease-resistant and β-sheet-rich isoform of PrPC (Prusiner 1991). A 'unified theory' of 
prion propagation defined by Charles Weissmann (Weissmann 1991) indicates that prion is 
an infectious protein that does not contain any informational nucleic acids, and propagates 
by recruitment and the “autocatalytic” conformational conversion of normal PrPC into disease-
associated PrPSc (Aguzzi, Heikenwalder et al. 2007). PrPC is soluble in mild detergents and 
sensitive to proteinase K (PK) digestion. PrPSc forms insoluble aggregates and is partially 
resistant to PK (Bolton, Mckinley et al. 1982, Oesch, Westaway et al. 1985, Meyer, Mckinley 
et al. 1986). Correlation of the mass of the purified PrPSc protein fractions to the infectivity 
showed that the most infectious prion particle has a mass corresponding to 14-28 PrP 
molecules (Silveira, Raymond et al. 2005). 
There have been two models proposed for the pathological conversion of PrPC into PrPSc 
(Figure 4.1): (A) the 'refolding' or template directed assistance model (Gajdusek 1988) and 
(B) the 'seeding' or nucleation–polymerization model (Jarrett and Lansbury 1993). In the 
'refolding' model, a kinetic energy barrier prevents the spontaneous misfolding from PrPC into 
PrPSc. An exogenously introduced PrPSc, probably with the assistance of a chaperone 
(Telling, Scott et al. 1995) or another type of molecule (Priola, Chesebro et al. 2003), acts as 
a template that catalyzes the conversion of PrPC into PrPSc (Weissmann 1999). In the 
'seeding' model, the natural equilibrium between PrPC and PrPSc is strongly shifted towards 
PrPC (Weissmann 1999). Exposure to monomeric PrPSc induces a nucleation-polymerisation 
process that promotes the stabilization of PrPSc and further recruitment of more monomeric 
PrPSc, which results in the formation of amyloid. The propagation through fragmentation is 
predicted as a crucial step that determines the degree of infectivity during prion replication 
(Knowles, Waudby et al. 2009, Cohen, Vendruscolo et al. 2011) 
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Figure 4.1 Models of prion replication. A. The 'refolding' or template-directed assistance model. B. 
The 'seeding' or nucleation–polymerization model. Figure adapted from (Aguzzi and Polymenidou 
2004). 
 
4.4 Prion pathogenesis 
The precise molecular mechanisms of prion pathogenesis that lead to glial activation, 
neuronal cell death and the association of PrPSc and prion plaques to neurotoxicity are not 
yet well understood. A basic question is whether prion diseases are caused by PrPC 
associated loss of function (Aguzzi, Baumann et al. 2008). First, PrPC deficient mice did not 
show a significant phenotype of prion-like neuropathological changes (Bueler, Fischer et al. 
1992), prion replication after intracerebral (i.c.) inoculation with prions was not observed 
(Bueler, Aguzzi et al. 1993), indicating that PrPC expression is necessary for prion replication. 
The Prnp-/- mice transplanted with PrPC overproducing neuroectodermal grafts into brains 
and intracerebrally inoculated with prions showed high levels of PrPSc accumulation and 
prion infectivity in grafts, and developed typical scrapie-induced histopathological changes. 
However, the surrounding tissue lacked PrPC expression and without pathological changes, 
suggesting that PrPC was required for scrapie – induced neurotoxicity (Brandner, Isenmann 
et al. 1996, Brandner, Raeber et al. 1996). Then, early signs of prion pathology such as 
spongiotic degeneration and neuronal cell loss were reversed by conditionally removing PrPC 
selectively in neurons after prion inoculation (Mallucci, Dickinson et al. 2003, Mallucci, White 
et al. 2007), confirming that scrapie – induced toxicity requires target cells expressing PrPC. 
Besides, transgenic mice that express a secreted PrP molecule lacking the 
glycosylphosphatidylinositol-anchor (GPI) were still able to replicate PrPSc but without any 
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signs of neurotoxicity (Chesebro, Trifilo et al. 2005), suggesting that PrP must be membrane-
bound to induce cellular toxicity. 
Some recent studies reported that prion replication and neurotoxicity may occur in two 
different phases: First, an exponential phase without clinical signs, where PrPC is misfolded 
into PrPSc and prion titers are exponentially increased. This phase is not rate limited by PrPC 
expression and prion infectivity can increase until a plateau is reached. Second, a plateau 
phase of prion infectivity determines the time to clinical onset and is inversely proportional to 
prion protein concentration (Sandberg, Al-Doujaily et al. 2011, Sandberg, Al-Doujaily et al. 
2014). These studies hypothesized a toxic PrP species termed PrPL that might be an 
oligomeric species of PrPSc. 
 
4.5 Prionoid in PMDs 
Protein misfolding disorders (PMDs) are classified by the coalescence of proteins into highly 
ordered aggregates that can affect entire organ systems with preferential deposition in the 
CNS, resulting in progressive neurodegeneration (Aguzzi and Lakkaraju 2016). So far, more 
than 20 different misfolding proteins have been reported, including mainly α-synuclein in 
Parkinson’s diseases (PD) and multiple system atrophy (MSA), amyloid precursor protein 
(APP) and tau in Alzheimer’s diseases (AD), transactive response DNA binding protein 43 
kDa (TDP-43) in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), 
huntingtin in Huntington disease, and amyloid polypeptide in systemic amyloid disorders 
(Aguzzi and Lakkaraju 2016). Some of the proteins have been recognized and characterised 
according to the cellular localization of protein deposits: in prion diseases, PrPSc aggregates 
in extracellular spaces; amyloid-β (Aβ) deposits in extracellular and cytoplasmic space in AD; 
in PD, α-synuclein deposits in cytoplasm; in Huntington’s diseases, polyglutamine 
accumulates in the nucleus.  
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Figure 4.2 Protein aggregates in neurodegenerative disease. (a) Senile plaques in the neocortex 
of a brain with AD. (b) NFTs in hippocampus of FTDP-17. (c) Lewy body in the substantia nigra of PD. 
(d) Intranuclear polyglutamine inclusion in neocortex of Huntington disease. (e) Ubiquitinated inclusion 
in spinal cord motor neuron of ALS. (f) Protease-resistant PrP in cerebellum of CJD. Figure adapted 
from (Forman, Trojanowski et al. 2004) 
 
The best-characterized PMDs are prion diseases that result from the aggregation of 
misfolded cellular prion proteins into highly ordered and β-sheet-enriched PrPSc. Although 
prion diseases are unique among neurodegenerative disorders because of their 
transmissibility between individuals and can cause epidemics, the ability of misfolding and 
self-propagation is not exclusive to prions. The amino acid sequence of each culprit protein 
in PMDs is different, but they all have a similarly insoluble and highly ordered structure 
containing β-sheets. The principles governing aggregation and propagation are quite similar 
to prions, in that under some certain conditions, the conformation of physiologically soluble 
proteins can change into β-sheet-enriched forms. Such protein aggregates spread from cell 
to cell, which triggers insolubility, aggregation propensity, and the resistance of protein 
aggregates to physical denaturants. Therefore, the term 'prionoids' (Aguzzi 2009) was 
applied to protein aggregates that act in a prion like manner but are not identical to prions, 
because they have not been found to be transmitted between humans. For example, the cell-
to-cell transmission of pathologic α-synuclein and Parkinson’s like Lewy pathology was found 
in wild-type (wt) non-transgenic mice with a single intracerebral injection of synthetic α-
synuclein (Luk, Kehm et al. 2012). Additionally, recent studies have shown that Aβ can seed 
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aggregates of identical conformation in a particular conformation (Stohr, Condello et al. 2014, 
Watts, Condello et al. 2014), and other studies have reported some evidence for human 
transmission of Aβ pathology and cerebral amyloid angiopathy (Jaunmuktane, Mead et al. 
2015, Frontzek, Lutz et al. 2016, Kovacs, Lutz et al. 2016). Therefore, fundamental studies 
focusing on the mechanisms of prion replication and prion-induced neurodegeneration can 
help advance the understanding the mechanisms of other PMDs diseases. 
 
4.6 Strategies for potential therapeutic targets of prion diseases 
Several strategies have been explored to target different stages of prion pathogenesis 
(Figure 4.2): a) Knock down the Prnp gene or pharmacologically down regulate PrPC to block 
conversion of PrPC into PrPSc; b) Specifically capture prions by antibodies or compounds to 
prevent the process of prion replication; c) Interfere with the formation of higher-order 
aggregates by antibodies or compounds; d) Stabilize prion fibrils by compounds to prevent 
the process of prion replication; e) Enhance natural protein-aggregate-clearing mechanisms 
by antibodies or compounds to prevent the process of prion replication; f) Use compounds to 
interfere with PrPC-mediated neurotoxic pathway at the neuronal cell membrane (Aguzzi, 
Nuvolone et al. 2013). 
To date, a large number of compounds have been screened with several compounds 
showing promising results in the suppression of prion proteins in cell-free or cell-based 
models, but showed no efficacy in follow-up validation using in vivo animal models. The 
majority of potential compounds showed little efficacy after the key pathologic features had 
occurred (Trevitt and Collinge 2006). Besides, antibody therapy has the inherent limitation 
that treatment should start before the onset of clinical signs (Aguzzi, Heikenwalder et al. 
2007). However, in patients treatment is normally initiated is after the clinical diagnosis is 
made, at late stages of the disease. Therefore, potential therapeutics must exhibit high 
efficiency after prion-related pathology is already present. Unfortunately, disease-modifying 
therapies are not yet available. Hopefully, better understanding of the fundamental molecular 
mechanisms of prion diseases will facilitate the discovery of novel therapeutic approaches. 
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Figure 4.2 Potential therapeutic targets at different stages of prion pathogenesis. Figure 
adapted from (Aguzzi, Nuvolone et al. 2013) 
 
4.7 Aims of the thesis 
For my PhD thesis, I have proposed to develop new methods and technologies available for 
high-throughput measurements of prion proteins and infectivity. Then, I intend to apply these 
high-throughput assays to large scale murine siRNA screens, to identify genes that are 
involved in endogenous PrPC expression and prion replication, to improve the understanding 
of molecular mechanisms of prions, and to find novel therapeutic targets for prion diseases.  
a) Develop homogeneous-phase fluorescent resonance energy transfer assays for mouse 
prion protein detection (PrPC-HPFRET, PrPSc-HPFRET). 
b) Establish a cell-based bioassay “DPICA” for prion infectivity measurement that can be 
adapted to a fully automated platform. 
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c) Establish an RNAi HTS system for a comprehensive genome-wide study of prion 
diseases by combining novel technologies (PrPC-/PrPSc-HPFRET, small RNAi, automated 
liquid handling platforms). 
d) Apply the RNAi HTS system to a mouse siRNA library screen to identify genes that 
regulate endogenous PrPC expression and prion replication. 
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5 Results PART I: Establishment of an automated digital 
prion infectivity cell assay (DPICA)  
5.1 Introduction 
5.1.1 Prion infectivity 
Prion diseases are characterized by the deposition within the CNS and other organs of PrPSc, 
a misfolded and aggregated isoform of the host-encoded PrPC, (Aguzzi and Zhu 2012). Prion 
diseases are unique among neurodegenerative conditions because of their transmissibility 
between individuals. The infectious agent consists of PrPSc, which acts as a propagon (Tuite 
and Cox 2003) capable of seeding a self-perpetuating reaction of templated nucleation 
(Aguzzi, Nuvolone et al. 2013). Because of these conditions, PrPSc concentrations are often 
used by scientists and regulatory agencies as surrogates of prion infectivity titers. However, 
this practice is fraught with problems. PrPSc is defined as the fraction of PrP that is resistant 
to proteolysis (Prusiner 1982), yet up to 99% of infectivity resides in a protease-sensitive 
fraction. Moreover, since the number of PrPSc monomers in each prion propagon is variable, 
infectious prion titers cannot be predicted by directly measuring PrPSc. These limitations 
indicate that it is unreliable to extrapolate prion titers from PrPSc determinations. Instead, 
accurate prion titrations continue to require bioassays in which infectivity is transferred to 
entities susceptible to infection. 
 
5.1.2 Conventional prion infectivity bioassays 
The standard prion infectivity assay is conducted by inoculating serial dilutions of the sample 
intracerebrally into indicator animals (Chandler 1961) and determining the dilution at which 
50% of the animals acquire scrapie (end-point method) (Reed J 1938, Dougherty 1964). This 
method requires vast cohorts of animals and is prohibitively expensive. Prusiner introduced 
the incubation time method (Bolton, Mckinley et al. 1982), which relies on the inverse 
relationship between the logarithm of the inoculum size and latency time of the clinical 
disease. The latter method requires much smaller number of animals, but is notoriously 
imprecise. Moreover, both animal bioassays require several months to years for completion. 
Furthermore, clinically apparent prion disease creates a significant animal-welfare burden.  
A landmark innovation was achieved by Charles Weissmann’s “scrapie cell assay in end-
point format (SCEPA)”(Klohn, Stoltze et al. 2003). The SCEPA takes 2-3 weeks to be 
completed, and is as sensitive as the mouse bioassay. In the SCEPA, prion susceptible cells 
are plated in 96-well plates and exposed to serial dilutions of prion-containing samples for 3 
days. Cells are consecutively split 1:10 for three times every 3 days. Finally, cells in each 
well are transferred to membranes of ELISPOT plates and PrPSc-positive cells identified by 
immunoblotting. The tissue culture infectivity 50% dose (TCID50) is calculated 
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accordingly(Reed J 1938, Dougherty 1964). Although the SCEPA significantly accelerates 
prion titrations, it still requires intensive pipetting for cell culture. Moreover, the handling of 
infectious culture medium can pose biohazards to the experimenters through the generation 
of highly infectious aerosols (Haybaeck, Heikenwalder et al. 2011). Moreover, the ELISPOT 
immunoreactions can only be partially automated. Here, we propose to develop a new cell-
based prion infectivity bioassay, which can be adapted to a fully automated platform, and is 
therefore suitable for HTS applications.  
 
5.2 Specific aims of the project 
Here, I planned to develop a new cell-based assay for prion infectivity detection, termed 
"digital prion infectivity cell assay (DPICA)". The DPICA was designed to be applicable for 
automation and high-throughput applications. 
a) Develop homogeneous-phase fluorescent resonance energy transfer assays for prion 
proteins detection (PrPC-HPFRET, PrPSc-HPFRET). 
b) Utilize PrPSc-HPFRET to establish a new cell-based bioassay (DPICA) for prion infectivity 
measurement, which can be adapted to a fully automated platform. 
c) Establish automated HPFRET and DPICA programs on our robotic platform. 
  
5.3 Development of HPFRET assays for detecting prion proteins 
Fluorescence resonance energy transfer (FRET) is based on the energy transfer between 
two fluorophores, Europium (Eu3+) and allophycocyanin (APC), which are separately labelled 
to anti-PrP antibodies (Table 5.1). When the Eu3+ and APC labelled anti-PrP antibodies bind 
to a single molecule and are closely apposed (<10 nm), the donor Eu3+ is excited and 
transfers the energy to the acceptor APC by nonradiative dipole-dipole coupling. Then the 
APC emits photons at a wavelength that can be measured. 
To measure prion proteins in a fast and automated manner, I# developed homogeneous-
phase FRET assays (HPFRET) for the quantification either  PrPC (Falsig, Sonati et al. 2012) 
or PrPSc. I established the HPFRET in a 96-well format and then optimized the assays for the 
384-well format.  
 
 
 
 
# I use the first-person narrative in my thesis in order to unequivocally identify those experiments that I 
personally performed, compared to when I use the “we” designation, which indicates that I was either 
involved in designing experiments, analysis and/or in the interpretation of the data. 
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5.3.1 Establishment of PrPC-HPFRET 
To detect PrPC in a homogeneous phase, a variety of anti-PrP holoantibody pairs (POMs) 
(Polymenidou, Moos et al. 2008, Sonati, Reimann et al. 2013) were labeled with Eu3+ and 
APC, respectively. I tested different FRET holoantibody pairs and found the best FRET pair 
for PrPC detection with the highest sensitivity and signal-to-noise ratio (SNR) is Eu2+-POM2 
and APC-POM1. The detection limit was about 0.4 ng/mL monomeric recombinant PrP 
(recPrP). In normal mouse brain homogenates (BH), PrPC was detectable when the brain 
homogenate was 50,000 times diluted. In CAD5 cell lysates, PrPC was detectable when the 
CAD5 cell lysate was diluted to 25 μg/mL (=1.25 μg/well total protein) (Figure 5.1). Normally, 
when the CAD5 cells are confluent in 384-well plates, there are about 5 μg/well total proteins, 
which is more than enough for PrPC-HPFRET. 
 
Table 5.1 Molecular characteristics of fluorophores used for labelling FERT antibodies.  
Fluorophore Molecular weight 
Excitation 
λmax 
Emission 
λmax 
Extinction 
coefficient Chemistry 
Reactive 
group 
Europium (Eu3+) 151 g/mol 340 nm 615 nm at 335nm: 27,500 cm-1M-1 
Amine reactive (-NH
2
) NHS ester 
Allophycocyanin 
APC 104 kDa 650 nm 665 nm 
at 650nm: 
700,000 cm-1M-1 Thiol reactive (-SH) 
Maleimide 
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Figure 5.1 Establishment of PrPC-HPFRET. (a) Comparison of FRET holoantibody pairs. Blue dot: 
normal mouse brain homogenate. Black dot: PrP-/- mouse brain homogenate. (b) PrPC titration in 
monomeric recPrPC. The FRET antibody pair was POM2-Eu2+ and POM1-APC. When the monomeric 
recPrPC was diluted to around 0.4 ng/mL, the PrPC signal was still detectable (***P<0.001). (c) PrPC 
titration in mouse BH. The sample was 1% NBH from C57BL/6 mouse, then 1:1 diluted with 1% Prnp-/- 
BH. The FRET antibody pair was POM19-Eu2+ and POM1-APC. When the NBH was 51,200 times 
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diluted, the PrPC signal was still detectable (*P<0.05). (d) PrPC titration in CAD5 cell lysate. The 
sample was 100 μg/mL CAD5 cell lysate, then 1:1 diluted with 100 μg/mL CAD5 Prnp-/- cell lysate. 
When the CAD5 cell lysate was diluted to 25 μg/mL (1.25 μg/well total protein), the PrPC signal was 
still detectable (***P<0.001). (e) Epitopes of the α-PrP antibody library. Adapted from (Sonati, 
Reimann et al. 2013) 
 
5.3.2 Establishment of PrPSc-HPFRET 
To detect PrPSc in the homogeneous phase (Figure 5.2a), tissue samples were 
homogenized in 0.32M sucrose or PBS and treated with a lysis/digestion buffer containing 
detergents and proteinase K (PK). Any cellular PrPC present in samples is fully degraded by 
PK, whereas PrPSc aggregates indicative of prion infection are PK-resistant and therefore 
preserved. After PK inactivation by PMSF, concentrated sodium hydroxide was added to 
disassemble PrPSc aggregates into monomers (Peretz, Scott et al. 2001), followed by 
phosphate buffer for pH neutralization. Residual PrP was detected by a mixture of two 
monoclonal antibodies (Polymenidou, Moos et al. 2008, Sonati, Reimann et al. 2013) 
directed against two non-overlapping epitopes of PrP and labeled Europium (Eu3+) and 
allophycocyanin (APC), respectively. By bridging the two antibodies, any PrP present in the 
sample enabled concentration-dependent FRET, thereby providing homogeneous-phase 
readout with extremely little background, a broad linear dynamic range, and sufficient 
sensitivity. I found that complete disassembly of PrPSc aggregates into monomers was crucial 
for obtaining an optimal FRET signal. We therefore titrated the NaOH concentration 
necessary to disassemble the PrPSc aggregate after PK digestion (Figure 5.2b). A 
concentration of 42 mM NaOH was found to increase the PrPSc FRET signal to a plateau, 
whereas higher concentrations did not improve the signal. Since 57 mM of NaOH resulted in 
a highest and least variable signal, it was defined as a standard concentration for following 
experiments.  
To apply the PrPSc-HPFRET to the assessment of PrPSc level in mouse samples, I tested 
various antibodies from the POM library developed in-house (Polymenidou, Moos et al. 
2008). Antibody pairs were scored according to the Z’ factor and the signal-to-noise (S/N) 
ratio of the assay, and were considered acceptable if the Z’ factor was ≥0.5 (with 1 being the 
maximum) and the S/N ratio was ≥5. Several antibody pairs were found to satisfy these 
requirements (Figure 5.2c). I used the FRET antibody pair Eu2+-POM19 and APC-POM1 to 
further validate the fast and robust readout of the PrPSc-HPFRET. In CD1 mice brains which 
were infected with the Rocky Mountain Laboratory (RML) (Mahal, Baker et al. 2007) prion 
strain, PrPSc signal was still detectable (****p < 0.0001) when the RML6 BH was 6,400 times 
diluted in 1% Prnp-/- mouse (Figure 5.2d). I also found a good FRET antibody pair Eu2+-3F4 
and APC-POM1 to detect PrPSc in 263K prion-infected hamster brain homogenates (BH, 
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Figure 5.2e). This antibody pair recognizes epitopes, which are conserved between mouse 
and human PrP (Polymenidou, Moos et al. 2008, Polymenidou, Prokop et al. 2011), and can 
therefore potentially be used for the detection of human PrPSc by HPFRET.  
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Figure 5.2 Establishment of PrPSc-HPFRET.  (a) Scheme of the PrPSc-HPFRET assay.  Samples are 
treated with PK digestion, denatured, and neutralized. Then PK-resistant PrPSc is determined by FRET 
using a donor-acceptor pair of antibodies to distinct PrP epitopes. (b) Titration of the NaOH 
concentration to disassemble PrPSc aggregates. The sample was 0.5% RML6 BH. Negative controls 
were 0.5% NBH and 0.5% Prnp-/- BH without denaturation. 57 mM NaOH was sufficient to increase the 
PrPSc-HPFRET signal to a plateau. (c) The samples were 0.5% RML6 BH, 0.5% NBH and 0.5% Prnp-/- 
BH. All the antibody pairs had a good Z’ factor>0.5 and a high S/N>5. The FRET pair Eu2+-POM19 
and APC-POM1 had the highest PrPSc-HPFRET signal. (d) PrPSc titration in prion infected mouse BH. 
1% RML6 BH was 1:1 serially diluted with 1% Prnp-/- BH. The FRET antibody pair was Eu2+-
POM19and APC-POM1. When the RML6 BH was diluted 6,400 times, the PrPSc signal was still 
detectable (****P<0.0001). (e) Samples were 0.5% BH from the 263K prion-infected hamster, 0.5% 
NBH from normal hamster and 0.5% BH from Prnp-/- mouse. The FRET antibody pair was Eu2+-3F4 
and APC-POM1. The PrPSc in hamster BH was significantly detectable (***P<0.001). 
 
To further validate the robust and high-throughput readout of PrPSc-HPFRET, I used the 
assay to detect PrPSc in various C57BL/6 mouse brain regions (hippocampus, frontal brain, 
cerebellum, cortex/midbrain and olfactory bulb) at 8 different time points of the prion 
incubation period (Figure 5.3a-e). The PrPSc-HPFRET results indicate that PrPSc were first 
detectable from 82~96 dpi at various brain regions and PrPSc levels were constantly 
increased to the end point of the incubation period. Hippocampus has the highest PrPSc level 
at the terminal stage (Figure 5.3f). In general, the HPFRET assays were found to be 
acceptably rapid, scalable, and sensitive. The new assays require minimal manipulation of 
samples and do not involve any washing, liquid-replacement, and centrifugation steps. In 
addition, it enables HTS-compatible detection of prion proteins and compliance with best 
biosafety practices. 
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Figure 5.3 Validation of PrPSc-HPFRET for automated high-throughput measurements. The 
samples were 0.5% tissue: (a) hippocampus, (b) cerebellum, (c) frontal brain, (d) cortex/midbrain and 
(e) olfactory bulb. Homogenates were prepared from the RML6 BH inoculated C57BL/6 mice. 
Negative controls were 0.5% NBH prepared from non-infectious CD1 BH inoculated C57BL/6 mice. 
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Four mice per time point. Serial dilutions of standard RML6 BH were included in each assay plate as a 
standard curve. Technical triplicates were done for each sample. The FRET antibody pair was Eu2+-19 
and APC-POM1. FRET signals of samples were normalized to standard RML6 BH. PrPSc was first 
detectable from 82~96 dpi at various brain regions (*P<0.05, **P<0.01, ***P<0.001) and constantly 
increased to the end point of incubation period. 
 
5.4 Establishment of digital prion infectivity cell assay (DPICA) 
5.4.1 Overview of DPICA scheme 
To apply the PrPSc-HPFRET, I established a cell-based homogeneous-phase bioassay for 
prion infectivity titration, which was designated the “Digital Prion Infectivity Cell Assay” 
(DPICA). When prion-containing test samples were subjected to limiting dilutions, the 
infection of individual wells containing susceptible cells was assumed to follow a Poisson 
distribution with each well assuming one of two binary states (infected vs non-infected, hence 
digital). We reasoned that the PrPSc-HPFRET could be optimally exploited for the binary 
assignment of parallel wells to either state in a high-throughput manner (Figure 5.4).  
First, a small number of prion-susceptible cells (typically 100 cells/well) were seeded in 384-
well microtiter plates, and exposed to limiting dilutions of prion-infected samples. Then, cells 
were cultured for 10 days (until cells reached confluence) to allow for prion replication without 
medium changes. Finally, cells were lysed directly in culture medium, and PrPSc was 
measured by PrPSc-HPFRET. In order to reliably extract prion infectivity measurements from 
potentially noisy raw signals, a numerical method (“Global Threshold Fitter”) was developed 
to iteratively apply a sliding series of thresholds to the global dataset until the solution 
converged onto the best estimate of infected vs non-infected wells. 
 
Figure 5.4 Scheme of DPICA. The whole procedure of DPICA takes about 11 days. The prion 
susceptible cells are seeded in 384-well plates and exposed to a highly diluted prion sample. The 
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post-infected cells are cultured for about 10 days for prion replication without medium change until the 
cells reach confluence. Then, the PrPSc-HPFRET is performed: cells are lyzed directly in culture 
medium; PrPC proteins are digested by PK; PK-resistant PrPSc aggregates are denaturated to 
monomers; pH is adjusted by neutralization for FRET; FRET antibody pair is added; the PrPSc level in 
each well is measured by the Envision reader and raw data files are reported. Finally, raw signal files 
are analysed by the “Global Threshold Fitter” and the prion infectivity titer of sample is calculated 
automatically. 
 
5.4.2 Numerical treatment of DPICA data 
For DPICA data analysis, we verify the thresholds over the entire data range and thereby 
obtain traces of the fraction of points below the threshold, with varying threshold. Then, we 
globally fit the fraction below the threshold to equations (1) at all thresholds and 
concentrations. 
𝑓𝑓𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 = �𝑃𝑃(𝑖𝑖)𝑄𝑄(𝑇𝑇, 𝑖𝑖) ∞
𝑖𝑖=0
 (1) 
P(i) in equations (1) is the probability mass function of the Poisson distribution. The number 
of prions in a given volume, for a fixed concentration, follows the Poisson distribution:  
𝑃𝑃(𝑖𝑖) = 𝜆𝜆𝑖𝑖𝑒𝑒−𝜆𝜆
𝑖𝑖!  (2) 
where “i” is the number of propagons and “λ” is the average number of propagons per unit of 
experimental volume, which can therefore be related to concentration by λ = c • V, where “V” 
is the volume of the sample and “c” is the concentration of propagons related to the initial 
propagon concentration c0 by the dilution D as c = c0/D. Therefore determining “λ” will allow 
determination of the initial concentration of propagons.  
Q(T, i) in equations (1) is the probability of below threshold “T”, given that it has “”" 
propagons. We define the probability distribution of signal intensity as S(y, i) (i.e. S(y, i) is the 
probability to obtain a signal of intensity “y”, given that there are “i” propagons in the sample). 
By integrating this distribution to a threshold “T”, we obtained the probability to yield a signal 
below the threshold for a given number of propagon “i”, which is Q(T, i). We assume the 
intrinsic spread in signal intensity, S(y, i), is still Gaussian in “y”, with the same standard 
deviation as the negative control and a mean, µ(i), which depends on the number of 
propagons i. Then Q(T; i) is given by the integral: 
 
𝑄𝑄(𝑇𝑇, 𝑖𝑖) = � 𝑆𝑆(𝑦𝑦, 𝑖𝑖)𝑑𝑑𝑦𝑦𝑇𝑇
−∞
= � 1
𝜎𝜎𝑛𝑛𝑛𝑛√2𝜋𝜋𝑇𝑇−∞ 𝑒𝑒−(𝑦𝑦−𝜇𝜇𝑛𝑛𝑛𝑛)22𝜎𝜎𝑛𝑛𝑛𝑛2 𝑑𝑑𝑦𝑦 = 12  erfc(𝜇𝜇(𝑖𝑖) − 𝑇𝑇√2𝜎𝜎𝑛𝑛𝑛𝑛 ) (3) 
where “erfc(x)” is the complementary error function of “x”. 
Based on the statistical model described above, we used the Python programming language 
to develop the “Global Threshold Fitter” software, by which the standard deviation σnc and 
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mean µnc of the negative control can be determined from experiments and the “λ” of the 
sample is calculated by the “Global Threshold Fitter” software automatically. 
 
5.4.3 Automation of DPICA 
We opted for a plate layout containing 352 experimental wells (288 wells/diluted sample, 64 
wells/negative control), 32 control wells. On a Perkin-Elmer Janus liquid handling platform, 
the procedure for plating out cells into 384-well plates and overlaying them with prion-
containing samples was found to average around 10 minutes/plate. Under typical production 
conditions, this translated to a throughput of 55,296 wells/24 hours. Since the optimal cell 
culture period was 10 days, sustained throughput required an automated cell-culture 
incubator interfaced with the liquid handling equipment and capable of hosting 144 384-well 
microplates. Finally, the readout sequence (including cell lysis, proteolysis of PrPC, 
disaggregation of PrPSc, and detection of residual PrP by FRET) had a maximal throughput 
of 15360 wells/24 hours. Considering that the prion titration of each sample required 352 
experimental wells and 32 control wells, amounting to 40 384-well microplates, the system 
allowed for precise infectivity determination of 20-40 samples/day.  
 
5.4.4 Validation of DPICA 
To assess the sensitivity of the DPICA, I prepared five samples (S1 to S5) by ten-fold serial 
dilutions (10-3 to 10-7) of the standard prion strain RML6 derived from CD1 mouse. The prion-
susceptible mouse neuronal cells CAD5 (Mahal, Baker et al. 2007) were seeded in 384-well 
plates and exposed to the five samples. Cells were cultured for 10 days, and PrPSc-HPFRET 
was performed using the antibody conjugate pair Eu2+-POM19 and APC-POM1. The global 
threshold fitting of plates (S1 to S5, S2 to S5) was analysed (Figure 5.5a), then each sample 
was analyzed separately (Figure 5.5b). The results demonstrated that there were about 55 
propagons/well in S1 plate, 16 propagons/well in S2 plate, 1.1 propagons/well in S3 plate, 
0.5 propagons/well in S4 plate and 0.01 propagons/well in S5 plate (Table 5.1). Since the 
limit of detection (LOD) of the PrPSc-HPFRET is around 10-4 dilution of RML6 BH (Figure 
5.2d), a positive signal reported by the DPICA from high dilutions (104 to 107) represented 
bona fide prion replication by the recipient CAD5 cells, which followed the linear dilution 
series. The sample S5 (10-7 dilution of RML6 BH) approached the LOD of DPICA in 384-well 
format, corresponding to about 3 propagons/plate.  
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Figure 5.5 Validation of DPICA using standard prion strain RML6. (a) The sensitivity of DPICA 
was determined by five samples (S1 to S5) prepared from ten-fold serial dilutions (10-3 to 10-7) of the 
standard prion strain RML6 BH. Prion-susceptible mouse neuronal cells CAD5 were seeded in 384-
well plates and exposed to the five samples. Cells were cultured for 10 days and PrPSc-HPFRET was 
performed using the antibody conjugate pair Eu2+-POM19 and APC-POM1. The global threshold fitting 
of plates (S1 to S5, S2 to S5) was analyzed. (b) Each sample was analyzed separately by the Global 
Threshold Fitter software and showed that there were about 55 propagons/well in S1 plate, 16 
propagons/well in S2 plate, 1.1 propagons/well in S3 plate, 0.5 propagons/well in S4 plate and 0.01 
propagons/well in S5 plate. 
 
To further validate the prion titration of RML6 BH, I performed three independent DPICA 
tests (Figure 5.6b) and confirmed that RML6 BH contains about 106.5 propagons/g. The prion 
titration of RML6 BH indicated that there was approximately ≤1 propagon/well in assay plates 
when RML6 BH was highly diluted to more than 10-5.  
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To assess the background signal of the DPICA, I performed the DPICA test using non-
infectious brain homogenates (NBH). CAD5 cells were seeded in 384-well plates and 
exposed to 104 dilutions of NBH from CD1 mice. Cells were cultured for 10 days, and PrPSc-
HPFRET was performed using the antibody conjugate pair Eu2+-POM19 and APC-POM1. 
The raw signals were analyzed by the Global Fitter software and showed that there was no 
propagon in NBH samples (Figure 5.6f), indicating that there is essentially no background 
when testing non-infectious materials by DPICA. Finally, I validated the robustness and 
versatility of the DPICA titration system using other mouse prion inocula (Figure 5.6c-e) 
(Table 5.1): Me7 (Mahal, Baker et al. 2007) BH derived from C57BL/6 mice, RML6-
inoculated C57BL/6 mice BH (RML6-C57BL/6) and RML6-inoculated Tga20 mice BH (RML6-
Tga20) (Fischer, Rulicke et al. 1996). 
 
 
 
Figure 5.6 Validation of the DPICA using different mouse prion inocula. (a) Prion infectivity was 
determined in several mouse prion inocula derived from different mouse strain CD1, C57BL/6, Tga20. 
The cell line was mouse prion susceptible neuronal cell CAD5. The FRET antibody pair was Eu2+-
POM19 and APC-POM1. (b) The prion inoculum was RML6 BH and the negative control was NBH 
from non-infectious CD1 mice. The infectivity titer of RML6 BH was determined as 106.5 propagons/g. 
(c) Prion inoculum was Me7 BH and the negative control was NBH from non-infected C57BL/6 mice. 
The infectivity titer of Me7 BH was determined as 105.4 propagons/g. (d) The prion inoculum was 
RML6-C57BL/6 BH and the negative control was BH from non-infected C57BL/6 mice. The infectivity 
titer of RML6-C57BL/6 BH was determined as 106.3 propagons/g. (e) The prion inoculum was RML6-
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Tga20 BH and the negative control was BH from non-infected Tga20 mice. The infectivity titer of 
RML6-Tga20 BH was determined as 107.0 propagons/g. (f) Sample was NBH from non-infectious CD1 
mouse. The result showed that there was no propagon in this non-infectious sample. 
 
Table 5.1 Validation of the DPICA with mouse prion inoculum 
Sample 
Global 
Threshold Fitter 
(Figure 5.5) medium 
ml/well 
C0 
(propagons/
ml) 
Propagons/ml 
sample 
Log 
propagons/ml 
sample 
Predicted value 
of Log 
propagons/ml 
sample from 
results of Fig. 
4b 
undiluted 
propagons/well 
S1 (10-3 RML6) 55 0.04 1'381 2.48E+03 3.14 3.45 
S2 (10-4 RML6) 16 0.04 403 4.03E+02 2.61 2.45 
S3 (10-5 RML6) 1.1 0.04 27 2.65E+01 1.42 1.45 
S4 (10-6 RML6) 0.5 0.04 13 1.34E+01 1.13 0.45 
S5 (10-7 RML6) 0.01 0.04 0.3 2.55E-01 -0.59 -0.55 
         
Sample 
Global 
Threshold Fitter 
(Figure 5.6) medium 
ml/well 
C0 
(propagons/
ml) 
Propagons/g 
tissue weight 
Log 
propagons/g 
tissue weight 
CV% 
undiluted 
propagons/well 
RML6_test1 1.14E+05 0.04 2'855'154 2'855'154 6.46 
8 RML6_test2 1.21E+05 0.04 3'031'091 3'031'091 6.48 
RML6_test3 1.03E+05 0.04 2'569'239 2'569'239 6.41 
Me7_test1 1.05E+04 0.04 263'048 263'048 5.42 
1 
Me7_test2 1.06E+04 0.04 265'067 265'067 5.42 
RML6- 
C57BL/6_test1 7.99E+04 0.04 1'998'635 1'998'635 6.30 
6 
RML6- 
C57BL/6_test2 8.69E+04 0.04 2'173'734 2'173'734 6.34 
RML6-
Tga20_test1 3.41E+05 0.04 8'530'082 8'530'082 6.93 
21 
RML6-
Tga20_test2 4.62E+05 0.04 11'562'264 11'562'264 7.06 
NBH_test1 0 0.04 0 0 Not Detectable 
  
NBH_test2 0 0.04 0 0 Not Detectable 
 
5.4.5 Comparison of the DPICA, SCEPA and mouse bioassay 
I compared the DPICA to the traditional mouse bioassay and SCEPA. RML6 BH was serially 
diluted and 30μl aliquots of each dilution were intracerebrally (i.c.) infected into each group of 
Chapter 5 
RESULTS PART I: Establishment of an automated digital prion 
infectivity cell assay (DPICA) 
 
35 
 
CD1 mice. Using the Reed-Muench formula (Reed J 1938), the infectivity of RML6 BH was 
calculated as 109.6 LD50 units/g. The SCEPA (Klohn, Stoltze et al. 2003) was performed in 96-
well plates for RML6 BH. Using the Reed-Muench formula (Reed J 1938), the infectivity of 
RML6 BH was found to be 106.8 TCID50 units/g. The DPICA was performed in 384-well plates 
for RML6 BH. Using the Global Threshold Fitter algorithm, the infectivity of RML6 BH was 
detected to be 106.5 propagons/g. The novelty of DPICA as a method to determine the 
absolute number of propagons in samples is based on a completely new model, delivering 
high sensitivity, while enabling sufficient throughput for large-scale HTS applications (Table 
5.2). 
 
Table 5.2 Comparison of the DPICA, SCEPA and mouse bioassay 
 DPICA SCEPA Animal 
Materials Prion susceptible cells Prion susceptible cells About 50 mice/sample 
Format 
In 384-well plates. 
288 wells/dilution. 
one dilution.  
In 96-well plates. 
12-24 wells/dilution. 
Serial dilutions from 
100% to 0% infected. 
6 mice/dilution. 
Serial dilutions from 
100% to 0% infected. 
Signal readout PrPSc-HPFRET ELISPOT-ELISA Clinical symptom 
Numerical 
treatment 
«Global Threshold Fitter» 
algorithm 
Median infectivity dose 
(ID50) model. 
Calculation: Reed-
Muench formula 
Median infectivity dose 
(ID50) model. 
Calculation: Reed-
Muench formula 
Time cost 11 days 2-3 weeks Several months 
Labor intensitity Fully automated system. 
Intensive labor for 
splitting cells and 
ELISPOT-ELISA. 
Moderate labor for 
mouse injection and 
frequently checking. 
Automation Full Half No 
High throughput Yes (20-40 plates/day) 
No 
(1-4 plates/day) No 
Prion titration 
report* 
(Log10 ± SD) 
Log propagons/g tissue 
weight 
RML6: 6.45 ± 0.04 
Log TCID50/g tissue 
weight 
RML6: 6.89 ± 0.52 
Log LD50/g tissue weight 
RML6: 9.62 ± 0.28 
 
5.4.6 Application of DPICA to assessment of prion decontamination 
The characterization of prion toxicity and replication may greatly profit from proteomics 
studies. However, it is difficult to justify the contamination of expensive mass spectrometers 
with prions. We therefore applied the DPICA to measuring prion removal during the pre-
analytical steps preceding mass spectrometry. Samples consisted of prion pellet aliquots 
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prepared from terminally sick, RML6-Tga20 mice BH. Before decontamination, prion 
infectivity in samples was ca. 105.8 propagons/sample as determined by DPICA (Figure 5.7a). 
We chose to assess four prion decontamination methods relying on distinct physical 
principles: chaotropic salt guanidinium hydrochloride (GdnHCl) with different detergents, 
nanofiltration, exposure to sodium hydroxide (NaOH), and exposure to concentrated formic 
acid (FA) (Figure 5.7a-b). After chemical treatment (6M GdnHCl, 1M NaOH, or 100% FA), 
samples were dialyzed against sterile PBS, and prion infectivity was determined by DPICA.  
CAD5 cells were seeded in 384-well plates and exposed to 1:40 or 1:60 dilution of a treated 
sample. Cells were cultured for 10 days, and PrPSc-HPFRET was performed using the 
antibody conjugate pair Eu2+-POM19 and APC-POM1. The raw signals were analyzed with 
the Global Threshold Fitter. We found that each of the three decontamination methods (1M 
NaOH and 100% FA, nanofiltration) reduced prion infectivity below detectability. Because the 
input infectivity was 105.8 propagons, we conclude that each of the procedures yielded a 
reduction of >5 log.  The decontamination method of 6M GdnHCl with 1% b-octylglucoside 
yielded a reduction of >3 log. Since the physical principles underlying each method of 
decontamination do not overlap, these data demonstrate a nominal total titer reduction of >18 
log. 
To understand the effect of GdnHCl and pH properties on the reduction of prion infectivity, 
we applied the DPICA to measure prion removal of samples treated with different GdnHCl 
concentrations and pH values. The detergent we used was 1% b-octylglucoside, which 
showed the best results in Figure 5.7a. The samples were aliquots from terminally sick, 
RML6-Tga20 mice BH, containing ca. 105.3 propagons/sample. After treatment of GdnHCl 
(from 0 to 5 M) at different pH (from 2.5 to 12), samples were dialyzed against sterile PBS, 
and prion infectivity was determined by DPICA. These results demonstrated that treatments 
of 5M GdnHCl and pH≤7.5 reduced prion infectivity below detectability, and the higher 
GdnHCl and the lower pH are more efficient to remove prions (Figure 5.7c). 
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Figure 5.7 Application of DPICA to assessment of prion decontamination. (a-b) The infectivity 
titer of prion pellet sample aliquots before decontamination treatment was 105.8 propagons/sample. 
After each treatment of 1M NaOH, 100% formic acid and Nanofiltration, the prion infectivity reduced 
below detectability, delivering a reduction of over 5 Log. The treatment of 6M GdnHCl with 1% b-octyl 
glucoside detergent yielded a reduction of over 3 Log. The treatment of 6M GdnHCl with other 
detergents roughly yielded a reduction of over 2 Log. (c) Determination of prion removal in GdnHCl 
(from 0 to 5 M) and pH (from 2.5 to 12) treated samples. The infectivity titer of RML6-Tga20 BH 
sample aliquots before treatment was 105.3 propagons/sample. After treatments of 5M GdnHCl and 
pH≤7.5, the prion infectivity reduced below detectability, delivering a reduction of over 5 Log. The 
higher GdnHCl and the lower pH were more efficient in reducing prion infectivity.  
 
5.4.7 Application of DPICA to assessment of prion infectivity in various mouse brain 
regions 
I applied the automated DPICA to measure prion infectivity in various brain regions 
(hippocampus, frontal brain, cerebellum, cortex/midbrain and olfactory bulb). C57BL/6 mice 
were i.c. inoculated with RML6 BH (30 µl of 0.1% BH containing 105 LD50 units) and 
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samples were collected at 8 time points: 27, 56, 82, 96, 123, 137 and 178 days post 
inoculation (dpi). At each time point, four mice were sacrificed and tissue samples from 
various brain regions were harvested. As a negative control group, four C57BL/6 mice were 
i.c. inoculated with uninfected 0.1% CD1 mouse BH. The prion titres in these brain regions 
were determined by the automated DPICA system (Figure 5.8). The DPICA results showed 
that different kinetics of prion propagation occurring in different brain regions. The prion titres 
at various regions reached a plateau at different time points: hippocampus (56 dpi) → 
cerebellum (82 dpi), frontal brain (82 dpi) → olfactory bulb (110 dpi) → cortex/midbrain (rises 
to terminal). The kinetics of prion infectivity propagation generally follows a sigmoid curve. 
 
Figure 5.8 Application of DPICA to assessment of prion infectivity in various mouse brain 
regions. The prion infectivity was measured in mouse brain TH of cortex/midbrain, cerebellum, frontal 
brain, hippocampus and olfactory bulb. Different brain regions showed different kinetics of prion 
propagation.  
 
5.5 Discussion 
Infectivity is the best-characterized biological property of prions. Instead, the basic physical 
properties of the prion, such as the exact number and atomic structure of PrP monomers 
included in one prion, are largely unknown. A precise, massively parallel method for prion 
infectivity determination would be instrumental in addressing many questions regarding basic 
prion science, diagnostic aspects as well as drug discovery against prion diseases.  
The Digital Prion Infectivity Cell Assay (DPICA), which is based on a homogeneous-phase 
FRET assay for prion proteins (PrPSc-HPFRET), offers far-reaching advantages over existing 
prion infectivity bioassays. In contrast to SCEPA, the DPICA does not require cell splitting 
and washing steps. All cell culture and subsequent reactions are carried out sequentially in 
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the same microwell, thus creating ideal preconditions for automation with simple liquid 
handling equipment.  
The high-density microplate format allows for dilutions of each sample to be tested in 288 
wells independently, whereas the mouse bioassay typically uses only 5-6 mice per dilution. 
Even SCEPA can only yield 12-24 wells per dilution. The larger number of measurements 
leads to vastly increased robustness of results. Moreover, the use of high-density 
microplates has allowed us to measure infectivity in extremely small samples.  
The "digital" properties of the DPICA originate from the property that each well can 
theoretically assume only one of two binary states, either infected or uninfected. In reality, 
however, acquisition of prion infectivity by a well containing several hundred cells is a 
gradual process, which can make it difficult to define a threshold for assigning a specific state 
to individual wells. This issue has been addressed by developing the "Global Threshold 
Fitter" statistical method. Rather than attempting to assign binary values to individual wells, 
the Global Threshold Fitter takes into account the entire collection of wells  and combines the 
Poisson statistical basis (Rissin and Walt 2006, Rissin, Kan et al. 2010) with analyses of 
bioassay signals and modeling of the reaction system (Klohn, Stoltze et al. 2003, Knowles, 
Waudby et al. 2009). Thus, DPICA is able to determine the prion titer with a much higher 
precision than the mouse bioassay and the SCEPA, which are based on the traditional 
median infectivity dose model (Reed J 1938, Dougherty 1964).  
 
5.6 Outlook 
For future prion studies, which requires the titration of a large number of samples and cannot 
be analysed by the mouse bioassay or SCEPA, I anticipate that the automated DPICA will 
provide a powerful platform for basic and applied prion research, including e.g. high-
throughput screens for the identification of chemicals interfering with prion secretion, 
infection, and/or replication (Karapetyan, Sferrazza et al. 2013), and genome-wide siRNA or 
CRISPR/Cas9 screens aimed at understanding the mechanisms of prion transmissibility and 
replication. 
 
5.7 Material and Methods 
5.7.1 PrPC-HPFRET 
Europium (Eu3+) donor and allophycocyanin (APC) acceptor fluorophores were coupled to 
anti-PrP holoantibodies POM1 and POM2 recognizing the globular domain and the 
octarepeats, respectively. The donor Eu2+-POM2 conjugate is excited at wavelength 340 nm 
and transfers energy to the acceptor conjugate APC-POM1 when the distance between 
acceptor and donor is <10 nm. POM1-APC then emits light at wavelength 665 nm, which can 
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be measured with a suitable time-resolving fluorescence. To detect PrPC level in 
homogenates, samples were lysed in 1x standard lysis buffer (50 mM Tris-HCl pH 8, 150 mM 
NaCl, 0.5% Na deoxycholate, and 0.5% Triton X-100, stored at room temperature (RT)). The 
Eu2+-POM2 and APC-POM1 antibody pair was added, FRET plate was sealed and shaking 
at 37°C for 1 h at 300 rpm. FRET signal of PrPC was detected by EnVision Multilabel Reader. 
 
5.7.2 PrPSc-HPFRET 
A homogeneous-phase Förster/fluorescence resonance energy transfer (FRET) assay was 
established for the measurement of PrPSc in tissue homogenates. Organ tissues were 
homogenized in 0.32 M sucrose (or PBS) to 10% (w/v, 100 mg of tissue per 900 µl 
homogenization buffer) and stored at -80°C. Chemicals for buffers were purchased from 
Sigma-Aldrich. 
PrPSc-HPFRET was performed in a 384-well FRET plate (white OptiPlate™-384 plates, 
PerkinElmer) with the following steps: 1) homogeneous sample was diluted with 1x standard 
lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 0.5% Na deoxycholate, and 0.5% Triton X-
100, stored at room temperature (RT)). 2) Digestion of PrPC: proteinase K (PK) (Roche) was 
added to the diluted sample, the FRET plate was sealed and shaking at 37°C for 1 hour at 
700 rpm. The PK concentration was related to total protein concentration of the diluted 
sample quantified by bicinchoninic acid assay (BCA). For 0.5 µg/µl total proteins, the final 
concentration for PK was 1 µg/ml. The total reaction volume was 50 µl/well. 3) Inactivation of 
PK: 4 µl/well of 30 mM PMSF (stored at -20°C) was added to reach a final concentration of  
2.2 mM. The FRET plate was sealed and shaking at RT for 10 min at 700 rpm. 4) 
Denaturation: to disassemble PK-resistant PrPSc aggragates to monomers, 7 µl/well of 
denaturing buffer (sodium hydroxide buffer containing 0.5M NaOH, pH 14.0, stored at RT) 
was added to reach a final concentration of 57.3 mM. The FRET plate was sealed and 
shaking at RT for 10 min at 700 rpm.  5) Neutralization: to adjust the pH for FRET, 8 µl/well 
of neutralizing buffer (phosphate buffer containing 0.5M NaH2PO4, pH 4.0, stored at RT) was 
added to yield a final concentration of 57.9 mM. The FRET plate was sealed and shaking at 
RT for 10 min at 700 rpm. 6) The FRET antibody pair incubation: Europium donor (Eu, 
Activated QuickAssay EU-1024 chelate kit was purchased from PELO Biotech) and the 
allophycocyanin acceptor (APC, AnaTagTM APC labeling kit was purchased from AnaSpec) 
fluorophores were coupled to anti-PrP holoantibodies(Polymenidou, Moos et al. 2008) 
POM19 and POM1 recognizing the different domain of mouse PrPSc, respectively. The Eu2+-
POM19 and APC-POM1 stock was diluted with 1x Lance buffer (LANCE® Detection Buffer 
for FRET,10x stock, diluted with dH2O for use) to 67.5 nM (concentration of POM antibody). 
6 µl/well of 67.5 nM Eu2+-POM19 and APC-POM1 was added separately. The final total 
volume was 81 µl/well. The FRET plate was sealed and shaking at 37°C for 1 h at 300 rpm. 7) 
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The FRET signal of PrPSc was detected by the EnVision Multilabel Reader. Donor Eu2+-
POM19 conjugate is excited at wavelength 340 nm and transfers energy to the acceptor 
conjugate APC-POM1 only when the FRET antibody pair binds to one protein with a distance 
<10 nm. APC-POM1 then emits light at wavelength 665 nm, measured by a time-resolved 
FRET reader. 
 
5.7.3 FRET calculation 
FRET is the number of APC channel counts that are due specifically to FRET. It is 
determined by subtracting the APC background and the adjusted europium background from 
the total counts. The FRET signal of each well is calculated by the following equation: FRET =  (Ta − Mean Aa) − [(Mean Ea − Mean Ba)/(Mean Ee − Mean Be)](Te − Mean Be) 
Here, 
Ta: test well signal, from APC channel. 
Te: test well signal, from europium channel. 
Aa: APC-POM1 blank, from APC channel (all reagents except Eu2+-POM19) 
Ea: Eu2+-POM19 blank, form APC channel (all reagents except APC-POM1) 
Ee: Eu2+-POM19 blank, form europium channel (all reagents except APC-POM1) 
Ba: buffer blank, form APC channel (all reagents except Eu2+-POM19 and APC-POM1) 
Be: buffer blank, form Europium channel (all reagents except Eu2+-POM19 and APC-POM1) 
 
5.7.4 Preparation of FRET antibody pairs 
The monoclonal full length POM antibodies were labelled in house for HPFRET assays. The 
donor fluorophore was Europium chelate (Eu-W1024 ITC chelate, AD0096, PerkinElmer). 
Coupling of proteins to Eu chelate occurs at alkaline pH via reaction of lysine residues and 
free N termini with the aromatic isothiocyanate group of the Europium chelate. To remove 
compounds interfering with labelling, proteins were dialyzed overnight. POM antibodies were 
diluted in 1 ml 100 mM sodium carbonate (Na2CO3), pH 9-9.3. Dialysis cassettes (Slide-A-
Lyzer®, Thermo scientific) were pre-incubated in ddH2O for 2 min and proteins were loaded 
with a 24G syringe. A dialysis cassette with a cut-off of 10-20 kDa was used for POM 
antibodies. Dialysis was done under stirring in a volume of 2 L of 100 mM Na2CO3 at 4°C 
overnight. Dialysis buffer was changed after 4-6 h of incubation at 4°C. Proteins and peptides 
were concentrated by Centricon concentrators (Millipore). Protein concentration was 
adjusted by the Bradford or BCA to a concentration of about 5 mg/ml. Lyophilized Eu-W1024 
ITC chelate (0.1 mg) was stored at - 20°C and immediately before use reconstituted in 100 μl 
distilled water which gives a concentration of 1.4 mM. A molar excess of 24x of Europium 
chelate over IgG was added into the protein (peptide) solution on ice and incubated in 100 
mM Na2CO3 over night at 4°C. Separation of the labelled protein from non-reacted chelate 
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was performed by size exclusion chromatography (Superdex 200 column, GE Healthcare). 
Elution from column was done with 50 mM Tris-HCl pH 7.8 + 0.9% sodium chloride. Sample 
fractions of 500 μl were collected. Superdex column was decontaminated with 10 mM 
phthalate buffer pH 4.1 containing 0.01% DTPA. Fractions were pooled and concentrated 
with Micron centrifugal filters (Amicon). Labelling ratio and concentration of labelled proteins 
were assessed by a Eu standard solution (Perkin Elmer) and Nano drop measurement, 
respectively. Aliquots of antibodies were stored in liquid nitrogen.  
Allophycocyanin (APC, AnaTagTM Labeling Kit 72111, Anaspec) was used as the acceptor 
fluorophore for conjugation to POM antibodies. Maleimide groups of APC react with 
sulfhydryl groups on the target antibody to form a covalent bond during conjugation. POM 
antibodies were concentrated to 2-10 mg/ml in a volume of 100 μl with Centricon 
concentrators (Millipore). Antibodies were reduced with 20 μl dithiothreithol (DTT) per mL of 
IgG solution for 30 min without agitation at room temperature. Depending on reaction volume, 
reduced antibodies were desalted either by spin or gravity columns. Protein concentration 
was assessed by Nanodrop. For the conjugation reaction, 1.5 mg of activated APC per mg 
reduced IgG was added to the reduced antibodies solution and incubated for 1 h at room 
temperature with agitation. By adding DMSO and NEM for 30 min at room temperature, free 
thiol groups were blocked. To remove free APC molecules from antibody solution, reaction 
mixture was purified via a protein G sepharose column (Sigma). The column was washed 
with water and 10 volumes of 20 mM phosphate buffer pH 7 to equilibrate. Samples were 
added and washed with five volumes 20 mM phosphate buffer pH 7. Flow through was 
collected. The column was eluted with 0.1 M glycine pH 2.3 and diluted with 1 M TrisHCl pH 
8. APC-labelled POM antibodies were characterized with Nanodrop (A280 and A650). 
Aliquots of antibodies were stored at 4°C and protected from light. 
 
5.7.5 Mouse prion susceptible cell line and prion inoculum 
Mouse cell line CAD-2A2D5 (CAD5) cells was derived from Cath.a-differentiated cells (Mahal, 
Baker et al. 2007). Mouse cell line N2aPK1 (Klohn, Stoltze et al. 2003) was a subclone of 
neuroblastoma cell line (N2a).  
20% RML6 brain homogenate (BH) was from Rocky Mountain Laboratory strain RML (RML; 
passage #6) infected CD1 mice by intracerebral inoculation (i.c.). 10% Me7 BH was from 
prion strain Me7-infected C57BL/6 (BL6) mice. 10% RML6-C57BL/6 BH was from RML6-
infected C57BL/6 mice. RML-Tg20 BH was from prion strain RML6-infected Tg20 mice. 
 
5.7.6 DPICA protocol 
1) Cell culture for DPICA  
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DPICA plate was 384-well ViewPlate plate (white, Optically Clear Bottom, TissueCulture 
Treated, Sterile, 384-Well with Lid, PerkinElmer). Cell culture medium (OFBS) was Opti-
MEM® I Reduced-Serum Medium (no phenol red) plus 10% FBS (HyClone), 1% 
GlutaMaxTM (Gibco) and 1% penicillin/streptomycin (Gibco).  
On day-1, 20 µl/well of CAD5 cells were plated to a density of around 100 cells/well. 16 hours 
after cell plating, a homogeneous mouse brain sample was diluted in OFBS medium to the 
level around 10-4 to 10-5 (w/v). Then, 20 µl/well infectious medium was added to the plates, 
corresponding to a homogenate with a tissue weight of 0.01 mg/ml and 0.001 mg/ml. The 
total final volume of culture medium was 40 µl/well. A whole 384-well plate was used for 
testing one dilution, so each sample required one DPICA plate. The dilution of the negative 
control (non-infectious sample) in each plate was the same as the sample dilution. Regular 
controls for reagents in all DPICA plates were the same: control+ was RML6 BH of 10-3 
dilution and the control- was CD1 BH of 10-3 dilution. After infection, DPICA plates were 
cultured in cell incubator (37°C, 5% CO2 and 95% humidity) for 10 days. 
 
2) PrPSc-HPFRET for DPICA  
On day-11, PrPSc-HPFRET was performed in DPICA plates with the following steps: 1) cell 
lysis and PrPC digestion in culture medium: 10 µl/well of 5x digestion buffer (5x standard lysis 
buffer containing 25µg/ml PK) was added directly without medium removal. The final 
concentration in each well was 1x standard lysis buffer and 5 µg/ml PK for about 105 cells. 
The DPICA plate was shaken at 37°C for 90 min at 700 rpm. 2) Inactivation of PK: 4 µl/well 
of 30 mM PMSF (stored at -20°C) was added to yield a final concentration of 2.2 mM. The 
DPICA plate was shaking at RT for 10 min at 700 rpm. 3) Denaturation: 7 µl/well of 
denaturing buffer (sodium hydroxide buffer containing 0.5M NaOH, pH 14.0, stored at RT) 
was added to yield a final concentration of 57.3 mM. The DPICA plate was shaken at RT for 
10 min at 700 rpm. 4) Neutralization: 8 µl/well of neutralizing buffer (phosphate buffer 
containing 0.5M NaH2PO4, pH 4.0, stored at RT) was added to yield a final concentration of 
57.9 mM. The DPICA plate was shaken at RT for 10 min at 700 rpm. 5) FRET antibody pair 
incubation: FRET antibody pair Eu2+-POM19 and APC-POM1 stock was diluted with 1x 
Lance buffer to 67.5 nM (concentration of POM antibody). 6 µl/well of 67.5 nM Eu2+-POM19 
and APC-POM1 was added separately. The final total volume was 81 µl/well. The DPICA 
plate was shaken at 37°C for 1 h at 300 rpm. 7) The DPICA plate’s clear bottom was sealed 
with white BackSeal-384 (PerkinElmer) for the top read of time-resolved FRET. The FRET 
signal of PrPSc was detected by EnVision Multilabel Reader. 
 
3) Mathematics for DPICA 
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The number of prions at a fixed concentration in a given volume, follows the Poisson 
distribution:  
𝑃𝑃(𝑖𝑖) = 𝜆𝜆𝑖𝑖𝑒𝑒−𝜆𝜆
𝑖𝑖!                                                                     (1) 
Where “i” represents the number of prions and λ is the average number of prions per unit 
experimental volume, and is therefore related to concentration by λ = c • V, where “V” is the 
volume of the sample and “c” the concentration of prions related to the original prion 
concentration c0 by the dilution D as c = c0/D. Therefore, determining “λ” will allow the 
determination of the original concentration of prions. However, it is not possible to simply fit a 
Poisson distribution to the distribution of signal intensities at a given concentration, as it is 
unclear how the signal strength scales with the number of prions. Nevertheless it should be 
possible to distinguish between samples that contain some prions and samples that do not 
have any prions at all and thereby determine P(i = 0), from which “λ” can be calculated. 
When we analyze the PrPSc-HPFRET data from a diluted concentration, we assume a certain 
threshold, T, has been chosen. Then the fraction of points below the threshold fbelow can be 
related to P(0) as follows: 
𝑓𝑓𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 = �𝑃𝑃(𝑖𝑖)𝑄𝑄(𝑇𝑇, 𝑖𝑖) ∞
𝑖𝑖=0
                                                       (2) 
This is the probability that the sample contains i prions, P(i), times the probability that the 
resulting measurement is below the threshold, given that “i” prions were in the sample, Q(T; 
i).  
We have included these conditional probabilities in order to account for experimental errors 
resulting in a spread of data, i.e., a sample containing no prions could still give a signal that 
is above the threshold and a sample containing some prions could give a signal below the 
threshold. For an ideal system with no spread, Q(T,0) = 1 and Q(T|i) = 0 for i ≠ 1, and 
therefore, the fraction of points below the threshold in this ideal case is equivalent to the 
probability of not having any prions, P(0). 
If we consider a real system with significant spread, we need to find expressions for the 
conditional probabilities, which will be functions of the threshold, and the number of prions, “i”. 
The probability to be below the threshold, “T”, if no prions are present, Q(T,0), can be 
determined from the negative control experiment: by fitting a Gaussian distribution to the 
distribution of negative controls, 
𝑄𝑄(𝑇𝑇, 0) = � 1
𝜎𝜎𝑛𝑛𝑛𝑛√2𝜋𝜋𝑇𝑇−∞ 𝑒𝑒−(𝑦𝑦−𝜇𝜇𝑛𝑛𝑛𝑛)22𝜎𝜎𝑛𝑛𝑛𝑛2 𝑑𝑑𝑦𝑦                                          (3) 
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i.e., we integrate the probability of obtaining a signal of intensity “y” to the threshold intensity. 
Calculating the probability of being below the threshold, if some prions are present, Q(T, i > 
0), is more complex. We can consider the question as consisting of two parts: one is the 
intrinsic spread, similar to the case above, due to differences in cell cultures, prion 
propagation, etc. The other part is the effect due to the variable number of prions injected 
into the system, which brings us back to the initial problem of having to relate the injected 
number of prions to the signal intensity, or rather, how the initial number of prions is related 
to the final concentration of PrPSc. 
We define the probability distribution of signal intensity as S(y, i), which is the probability to 
obtain a signal of intensity “y”, given that there are “i” prions in the sample. By integrating this 
distribution up to a threshold “T”, we obtain the probability to obtain a signal below the 
threshold for a given number of prions “i”, which is Q(T, i). We assume the distribution of 
intrinsic spread in signal intensity, S(y, i), is still Gaussian in “y”, with the same standard 
deviation as the negative control and a mean, µ(i), which depends on the number of prions i. 
Then, Q(T; i) is given by the integral 
 
𝑄𝑄(𝑇𝑇, 𝑖𝑖) = � 𝑆𝑆(𝑦𝑦, 𝑖𝑖)𝑑𝑑𝑦𝑦𝑇𝑇
−∞
= � 1
𝜎𝜎𝑛𝑛𝑛𝑛√2𝜋𝜋𝑇𝑇−∞ 𝑒𝑒−(𝑦𝑦−𝜇𝜇𝑛𝑛𝑛𝑛)22𝜎𝜎𝑛𝑛𝑛𝑛2 𝑑𝑑𝑦𝑦 = 12  erfc(𝜇𝜇(𝑖𝑖) − 𝑇𝑇√2𝜎𝜎𝑛𝑛𝑛𝑛 )                 (4) 
where erfc(x) is the complementary error function of “x”. 
When we analyze the PrPSc-HPFRET data, we vary the thresholds over the entire data range 
of all dilution curves and thereby obtain traces of the fraction of points below the threshold, 
with varying threshold for each concentration. Then, we globally fit the fraction below the 
threshold to equation 2 at all thresholds and concentrations. 
 
5.7.7 Automated liquid handling platform 
The fully automated DPICA program was established on the Janus liquid handling platform 
including the instruments: “JANUS Varispan + MDT Automated Workstation” (PerkinElmer), 
robotic cell incubator (LICONIC), EnVision Multilabel Reader (PerkinElmer). The automated 
DPICA program is fully automated with the running controlled by “JANUS Project Manager” 
scheduling software (PerkinElmer). 
 
5.7.8 Sample preparation from various mouse brain regions 
Animal care and experimental protocols were performed in accordance with the “Swiss 
Ethical Principles and Guidelines for Experiments on Animals” and with the Swiss Animal 
Protection Law, under the approval of the Veterinary office of the Canton Zurich (animal 
permit 41/2012). All efforts were made to minimize animal discomfort and suffering. 
C57BL/6J male mice were purchased from Charles River. Mice were kept in a conventional 
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hygienic grade facility, housed in groups of 3-5 in type IIL cages, under a 12 h light/12 h dark 
cycle (light from 7 am to 7 pm) at 22±1°C, with unrestricted access to sterilized food (Kliba 
No. 3340, Provimi Kliba, Kaiseraugst, Switzerland) and water. 
Mice were anesthetized with isofluorane and injected in the right hemisphere with 30 μl of 0.1% 
of RML6 or of 0.1% of NBH from CD-1 mice as control. Prion-infected and control mice were 
sacrificed at 4, 8, 12, 16, 18 and 20 weeks post-inoculation (wpi) or when they reached the 
terminal stage of prion disease. An additional group of control mice injected with NBH was 
sacrificed one week after the last prion-injected mouse reached the terminal stage. 
Euthanasia was performed by transcardial perfusion with PBS after deep anesthesia with 
ketamine and xylazinium. Brain areas were dissected, snap frozen and kept at -80°C until 
further processing. Ten percent (w/vol) tissue homogenates were prepared in 0.25 M 
sucrose in PBS using a Ribolyzer (Bio-Rad). 
 
5.7.9 Scrapie cell assay in end point format 
17,500 cells/well prion-susceptible neuroblastoma cells N2aPK were plated in 96-well plates 
and exposed to 300-µl brain homogenates using 6-12 replicas per dilution (ten-fold serial 
dilution from 10−3 to 10−8) for 3 days. Cells were subsequently split three times 1:10 every 3 d. 
After the cells reached confluence, 25’000 cells from each well were filtered onto the 
membrane of ELISPOT plates, treated with PK (0.5 µg/ml for 90 min at 37°C), and denatured. 
PrPSc-positive cells were identified by immunocytochemistry using alkaline phosphatase-
conjugated POM1 mouse anti-PrP and an alkaline phosphatase-conjugated substrate kit 
(Bio-Rad). Samples were quantified in endpoint format by counting positive wells according 
to established methods (Klohn, Stoltze et al. 2003). 
 
5.7.10 Mouse bioassay 
Serial dilutions of the 20% RML6 BH were prepared with PBS containing 5% BSA. CD1 mice, 
about eight week old, were intracerebrally (i.c.) inoculated with 30 μl of serially diluted RML6 
BH. In parallel groups, CD1 mice were intraperitoneally (i.p.) inoculated with 100μl 30 μl of 
serially diluted RML6 BH. Mice were monitored every second day for the occurrence of 
clinical signs and were euthanized at the terminal stage of prion disease. 
 
5.7.11 Preparation of prion decontaminated samples 
Brain tissue was harvested from RML6 inoculated Tga20 (Fischer, Rulicke et al. 1996) 
(RML6-Tg20) mice at terminal stage and stored frozen at -80°C. Semipurified PrPSc samples 
were prepared according to the procedure described by Xanthopoulos (Xanthopoulos, 
Polymenidou et al. 2009), excluding Proteinase K treatment.  
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1) Decontamination with chaotropic salt guanidinium hydrochloride (GdnHCl) 
The semipurified PrPSc sample was homogenized with Potter homogenisator in 6 M GdnHCl 
(Prusiner, Groth et al. 1993, Caughey, Raymond et al. 1997) (G4505, Sigma) solution in 
20mM HEPES, 5mM imidazole, 0.5M NaCl, pH7.5 containing 1% of the one of the following 
detergents: C8E4 (T3394, Sigma), b-octylpyranoside (O8001, Sigma), and incubated for 24h 
at 25°C with constant agitation.  
To eliminate cytotoxic GdnHCl and detergents from the samples, prior analysis by DPICA 
samples were either dialysed or the protein was precipitated. Dialysis was done against PBS 
using Slide-A-Lyzer Dialysis Cassettes, 10K MWCO (Pierce) with exchanges of the dialysis 
buffer after 2, 4, 16 and 24 hours of dialysis.  Protein was precipitated after dilution of the 
sample to 1M GdnHCl with 10% cold TCA (final concentration) and subsequently washed 
with cold ethanol. Resulting samples were harvested and the changes in protein loss were 
assessed with BCA assay (Pierce). 
 
2) Decontamination with NaOH 
The semipurified PrPSc sample was homogenized in 1M NaOH (Prusiner, Groth et al. 1981, 
Bauman, Lawrence et al. 2006, Unal, Thyer et al. 2007, Bellon, Comoy et al. 2014) and 
incubated for 24h. Afterwards sample were dialyzed against PBS using Slide-A-Lyzer 
Dialysis Cassettes, 10K MWCO (Pierce) with exchange of the dialysis buffer after 2, 4, 16 
and 24 hours of dialysis. 
 
3) Decontamination with formic acid 
The semipurified PrPSc sample with 100% formic acid (Brown, Wolff et al. 1990, Taylor, 
Brown et al. 1997) for 24h. Afterwards samples were dialyzed against PBS using Slide-A-
Lyzer Dialysis Cassettes, 10K MWCO (Pierce) with exchange of the dialysis buffer after 2, 4, 
16 and 24 hours of dialysis. 
 
4) Decontamination with nanofiltration (Golker, Whiteman et al. 1996, Tateishi, Kitamoto et 
al. 2001) 
The semipurified PrPSc sample was homogenized in PBS, then filtered through Sartorius 
filters Vivaclear (polyethersulfone, 0.8 μm, cat#VK01P042) at 14000g for 45min, followed by 
filtration through Vivaspin 6 (polyethersulfone, 0.2 μm, cat# VS0671) at 4000g for 1h and 
finally through Vivaspin 15R Hydrosart Membrane (2000 MWCO,  cat# VS15RH91) for 15h. 
Changes of the sample volume were noted. 
 
5) Decontamination with different GdnHCl concentrations and pH values 
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The RML6-Tg20 BH samples were homogenized with Potter homogenisator in (0, 1.7, 2.5, 
3.3, 4.2, 5.0 M) GdnHCl (G4505, Sigma) solution in 20mM HEPES, 5 mM imidazole, 0.5 M 
NaCl, pH (2.5, 5.0, 7.5, 12) containing 1% of b-octylpyranoside (O8001, Sigma), and 
incubated for 48h at 25°C with constant agitation. Dialysis was done against PBS using 
Slide-A-Lyzer Dialysis Cassettes, 10K MWCO (Pierce) with exchange of the dialysis buffer 
after 2, 4, 16 and 24 hours of dialysis. 
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6 Results PART II: Establishment of an automated PrP-
HPFRET based high-throughput siRNA screening 
platform 
6.1 Introduction 
6.1.1 RNA profile change upon prion infection 
Upon prion infection of neuronal cell lines, transcriptome profile changes reflect the direct 
response to prion and could indicate potential pathways of prion pathogenesis. Using a 
cDNA microarray, distinct expression profiles in ScN2a and ScGT1 cell lines were reported 
(Greenwood, Horsch et al. 2005). However, by applying high-density oligonucleotide 
microarray analysis and exhaustive bioinfomatical interrogation of the data, another 
transcriptional study analyzed the transcriptome of several prion infected cell lines (N2aPK1, 
CAD and GT1) under more stringently controlled conditions and identified only modest 
differential expression after prion infection (Julius, Hutter et al. 2008). The discrepancy 
between the two studies may due to differences in experimental design, cell culture 
conditions and/or prion infection processes. The transcriptional profile of cell culture might 
change after prion infection. The transcriptome of cell lines could also affect the susceptibility 
to prion infection. Different cell lines have distinct susceptibilities to prion infection. These 
differences cannot be explained by the PrPC expression levels alone, which are required but 
not sufficient for prion replication (Mahal, Baker et al. 2007). By comparing the transcriptome 
of prion-resistant revertants to susceptible cells, Marbiah et al. identified a gene regulatory 
network for extracellular matrix remodeling that was associated with prion propagation 
(Marbiah, Harvey et al. 2014). By using microarray and RT-PCR, miRNA expression 
changes were profiled in the brains of mice intracerebrally inoculated with mouse scrapie. 
Fifteen miRNAs were found to be de-regulated during the disease and only has previously 
been shown to be de-regulated in neurodegenerative disease (Saba, Goodman et al. 2008). 
With proper experimental strategy and the application of new RNA analysis technologies 
such as RNA sequencing (RNAseq), the understanding of the cellular transcriptional 
response to prion infection will be deepened. The identification of RNA profile changes upon 
prion infection may have potential as a biomarker for prion diagnostics and as a target for 
therapeutics. 
 
6.1.2 Small RNAs based targets identification for prion disease 
PrPC is indispensable for prion replication and prion-induced pathogenesis. Mice devoid of 
PrPC showed resistance to prion infection (Bueler, Aguzzi et al. 1993). A 50% reduction of  of 
PrPC (Prnp+/- heterozygous mice) significantly prolongs the incubation time of prion disease in 
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mouse, while overexpression of PrPC markedly shortens prion disease progression (Manson, 
Clarke et al. 1994). Therefore, the identification of genes involved in PrPC biosynthesis by 
small RNA based screening, and RNA-mediated modulation the PrPC expression have great 
potential to mitigate the PrPC-PrPSc conversion, diminish prion-induced neurotoxicity and 
consequently slow disease progression. 
Since Prnp is the main determinant for prion pathogenesis, small RNAs specifically and 
directly targeting Prnp have been extensively studied for prion therapeutics both in vitro and 
in vivo. siRNA duplexes targeting Prnp gene effectively suppressed the expression of PrPC in 
prion-infected N2a cells and inhibited the PrPSc accumulation (Daude, Marella et al. 2003). 
The liposome-siRNA-peptide complex was later developed to suppress PrPC expression and 
eliminate PrPSc formation in prion-infected N2a cells (Pulford, Reim et al. 2010). Additionally, 
the vector-based shRNA was successfully applied to decrease PrPC expression in rabbit 
kidney epithelial cells (Tilly, Chapuis et al. 2003) and mouse N2a cells (Mahal, Baker et al. 
2007). Lentiviral vector delivered shRNA also decreased PrPC levels and extended the 
incubation time in mice (Pfeifer, Eigenbrod et al. 2006, White, Farmer et al. 2008). Similar 
effects were observed in transgenic livestock (Golding, Long et al. 2006, Wongsrikeao, Sutou 
et al. 2011), Therefore, RNAi based Prnp knockdown represents a promising approach for 
prion therapeutics. However, certain considerations about RNAi based therapeutics, such as 
immunogenicity, cytotoxicity induced by off-target must be taken into account. Hence, a 
modified version of small RNA or novel small RNA targeting Prnp may circumvent those 
pitfalls. Recently, miRNA (Kang, Roh et al. 2011), DNA-based antisense oligonucleotides 
(ASO) (Nazor Friberg, Hung et al. 2012), and RNA aptamers (Weiss, Proske et al. 1997, 
Proske, Gilch et al. 2002) targeting Prnp/PrPC have been studied as a method to prevent 
prion disease progression. 
 
6.1.3 HTS applications for discovering prion therapeutic target 
PrPC is indispensable for prion replication and prion-induced pathogenesis. Mice devoid of 
PrPC showed resistance to prion infection (Bueler, Aguzzi et al. 1993). A 50% reduction of  
PrPC (Prnp+/- heterozygous mice) significantly prolongs the incubation time of prion disease in 
mouse, while overexpression of PrPC markedly shortens prion disease progression (Manson, 
Clarke et al. 1994). Therefore, the identification of genes involved in PrPC biosynthesis by 
small RNA based screening, and RNA-mediated modulation the PrPC expression have great 
potential to mitigate the PrPC-PrPSc conversion, diminish the prion-induced neurotoxicity and 
consequently slow disease progression. PrPC is indispensable for prion replication and prion-
induced pathogenesis. Mice devoid of PrPC were resistant to prion infection (Bueler, Aguzzi 
et al. 1993). Because Prnp is the main determinant for prion pathogenesis, small RNAs 
specifically and directly targeting Prnp have been extensively studied for prion therapeutics. 
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siRNA duplexes targeting Prnp gene effectively suppressed PrPC expression in mouse 
neuronal N2a cells and inhibited prion replication (Daude, Marella et al. 2003). Later, a 
liposome-siRNA-peptide complex was developed to suppress PrPC expression and eliminate 
PrPSc accumulation in N2a cells (Pulford, Reim et al. 2010). The vector-based shRNA was 
applied to decrease PrPC expression in rabbit kidney epithelial cells (Tilly, Chapuis et al. 
2003) and mouse N2a cells (Pfeifer, Eigenbrod et al. 2006). The lentiviral vector delivered 
shRNA also decreased PrPC level and extended the incubation time in mice (Pfeifer, 
Eigenbrod et al. 2006, White, Farmer et al. 2008), Similar effects were observed in 
transgenic livestock (Golding, Long et al. 2006, Wongsrikeao, Sutou et al. 2011). Therefore, 
RNAi based Prnp knockdown represents a promising approach for prion therapeutics. 
However, there are considerations about RNAi based therapeutics, such as immunogenicity, 
cytotoxicity induced by off-target that needs to be taken into account. Hence, a modified 
version of small RNA or novel small RNA targeting Prnp may circumvent those pitfalls. 
Recently, miRNA (Kang, Roh et al. 2011), DNA-based antisense oligonucleotides (ASO) 
(Friberg, Hung et al. 2012), and RNA aptamers (Weiss, Proske et al. 1997, Proske, Gilch et 
al. 2002) targeting Prnp/PrPC have been studied to prevent the prion disease progression. 
In addition, small RNA based high throughput screening (HTS) is expected to be used in the 
prion field. However, this application is challenging because the conventional approaches for 
prion proteins quantification are either time consuming or demand substantial manual work, 
hence are not applicable for HTS. Therefore, new methodologies and technologies 
complementary to an automated high-throughput system are required that facilitate HTS of 
entire small RNA libraries including siRNA, shRNA or  newly developed sgRNA libraries, 
compounds and peptides towards the identification of disease relevant genes, proteins, early 
molecular markers and novel therapeutics (Hruska-Plochan, Li et al. 2015).  
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Figure 6.1 Novel strategies for RNAi HTS to discover prion molecular mechanisms and 
therapeutic targets. Figure adapted from (Hruska-Plochan, Li et al. 2015). 
 
6.2 Specific aims of the project 
Here, I planned to combine the PrP-HPFRET assays and RNAi HTS technologies to 
establish an automated PrP-HPFRET based high-throughput siRNA screening platform, and 
to apply a siRNA library screen to identify genes affecting cellular prion protein expression 
and replication. 
a) Apply PrPC-HPFRET and PrPSc-HPFRET for assessing RNAi-mediated gene silencing in 
mouse neuronal cells. 
b) Establish an automated PrP-HPFRET based high-throughput siRNA screening platform. 
c) Apply the siRNA HTS platform for an arrayed murine siRNA library screen to identify 
genes regulating endogenous PrPC expression and prion replication. 
 
6.3 Application of PrPC-HPFRET and PrPSc-HPFRET for assessing 
RNAi-mediated gene silencing in neuronal cells 
To expand the power of PrPC-HPFRET and PrPSc-HPFRET to RNAi HTS technologies, I 
utilized them to determine RNAi-mediated gene silencing and block of prion replication. The 
siRNAs targeting mouse Prnp mRNA were used to develop the new assays in a mouse 
neuronal cell line Cath.a differentiated cell line 2A2D5 (CAD5), which is susceptible to 
various mouse prion strains (Weissmann, Li et al. 2011). CAD5 cells were plated in a 384-
well plate and transfected with Prnp-siRNA. After 72 hours incubation, cell viability assay and 
PrPC-HPFRET (Figure 6.2a) were performed to quantify PrPC. I found two out of four Prnp-
siRNAs (Prnp-siRNA1 and Prnp-siRNA4) could efficiently reduce Prnp expression. Since the 
PrPC level is the most important determinant for prion infection and replication, and it has 
been reported that knockdown of Prnp significantly reduces prion replication in vivo, Prnp-
siRNA silencing was expected to also reduce prion replication in vitro. Next, CAD5 cells were 
plated in a 384-well plate and treated with Prnp-siRNA for 24 hours, then exposed to RML6. 
72 hours after infection, cell viability assay and PrPSc-HPFRET (Figure 6.2b) were performed 
to quantify PrPSc. The results confirmed that both Prnp_siRNA1 and Prnp-siRNA4 could 
significantly block PrPSc replication in CAD5 cells. Besides, a Prnp gene knockout cell line 
(Prnp-/- CAD5) was generated by CRISPR/Cas9 technology and used as a control for cell-
based HPFRET assays. The newly developed assays for assessing RNAi-mediated gene 
silencing in neuronal cells confirmed that silencing Prnp gene could efficiently downregulate 
PrPC expression, and significantly block PrPSc replication. Therefore, PrPC-HPFRET and 
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PrPSc-HPFRET can be well combined with RNAi HTS to identify genes that affect prion 
protein expression and replication. 
 
Figure 6.2 Apply PrP-HPFRET assays to assessing RNAi-mediated gene silencing. (a) 2800 
cells/well CAD5 cells were plated in a 384-well plate and transfected with Prnp-siRNA. After 72 hours, 
cell viability assay and PrPC-HPFRET were performed to quantify PrPC protein in cell lysate (Relative 
PrPC level = relative PrPC-HPFRET / Relative cell number). Prnp-siRNA1and Prnp-siRNA4 efficiently 
downregulated PrPC by more than 80% and 50% (****P<0.0001). (b) 2000 cells/well CAD5 cells were 
plated in a 384-well plate and transfection with Prnp-siRNA  for 24 hours, then exposed to RML6 for 
72 hours. PrPSc-HPFRET and cell viability assay were performed to quantify PrPSc protein in cell lysate 
(Relative PrPSc level = relative PrPSc-HPFRET / Relative cell number). Prnp-siRNA1 and Prnp-siRNA4 
efficiently downregulated PrPC and thus significantly blocked PrPSc replication (****P<0.0001, 
***P<0.001). 
 
6.4 Establishment of an automated siRNA HTS platform 
Our lab has established the Labcyte Echo acoustic liquid handling platform and a Perkin-
Elmer Janus liquid handling platform for high-throughput applications (Figure 6.3a). Based 
on these robotic platforms, I established automated protocols specifically for the murine 
siRNA screening project. The Labcyte Echo acoustic liquid handling platform is able to make 
siRNA stamps in 384-well plates with a completely random map (Figure 6.3b): 1) siRNA 
controls are dispensed using “Plate Reformat” program; 2) siRNA samples are dispensed 
using “Cherry Pick” program with sample picking lists. In each screening plate, there are 48 
wells of nontarget-siRNA control, 47 wells of Prnp-siRNA1 control, 16 wells of Prnp-/- CAD5 
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cell control, and 192 wells of siRNA samples. I adapted these newly developed assays 
described above to a Perkin-Elmer Janus liquid handling system integrated with a Envision 
multilabel plate reader and a Liconic robitic incubator capable of hosting 44 384-well 
microplates. Under typical production conditions, this translated into a throughput of 15’360 
wells/24 hours, enabling sufficient throughput for large-scale HTS applications.  
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Figure 6.3 An automated RNAi HTS platform. The siRNA stamps in 384-well plates are made on a 
Labcyte Echo acoustic liquid handling platform; siRNA transfection and HPFRET assays are 
performed on a Perkin-Elmer Janus liquid handling platform. 
 
6.5 HTS of 3127 murine siRNAs targeting 780 genes involved in 
endocytosis pathways 
6.5.1 Screen of an arrayed murine siRNAs to identify genes regulating endogenous 
PrPC expression 
First, I did a genome-wide transcriptome analyses in 
CAD5 cells by RNAseq, which showed that there are 
13'752 genes expressed in the CAD5 cells line. 
Based on RNAseq results, I collected an arrayed 
murine siRNA library (offered by Novartis Institute for 
BioMedical Research) including 3’127 siRNAs 
targeting 780 genes that are expressed in CAD5 
cells and involved in endocytic membrane trafficking 
pathways.  
Then, I performed a screen of this library on our 
automated RNAi HTS platform: 1) All siRNA samples 
were randomly distributed into 384-well screening 
plates by the Echo liquid handler according to the 
completely random map (The screening plates were 
stored in -40°C freezer and thawed before use); 2) 
CAD5 cells were plated in screening plates and 
transfected with siRNAs. After 72 hours incubation, 
the cell viability assay and PrPC-HPFRET was 
performed on automated HTS platforms. The 
luminescent and FRET signals were read by 
EnVision multilabel plate reader. All the screening 
raw data were collected and then analyzed by 
collaborated bioinformaticians for quality control (QC) 
reports, normalization, hits selection and pathway 
analysis. 
 
6.5.2 Screen raw data analysis 
Based on screening the raw data, the bioinformaticians did QC analysis to ensure that the 
resulting data meet minimum quality standards in order to derive valid conclusions. The QC 
 
Overview of a murine siRNA library 
screen. 
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reports including heat map of PrPC-HPFRET (Figure 6.4) and Realtime-Glo signals (Figure 
6.5), smoothed histogram of control and sample distributions (Figure 6.6), showed that the 
screening raw data meets acceptable performance criteria for HTS.
 
Figure 6.4 QC report: Heat map of PrPC-HPFRET of screening plates (Group A to I, in total 32 
plates). 
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Figure 6.5 QC report: Heat map of Realtime-Glo of screening plates (Group A to I, in total 32 
plates). 
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Figure 6.6 QC report: Smoothed histogram of the control and sample distributions of screening 
plates (Group A to I, in total 32 plates). 
 
6.5.3 Silencing Tfr1 efficiently downregulated PrPC and blocked PrPSc replication in 
neuronal cells 
I found an interesting hit transferrin receptor 1 (Tfr1) by noting that three out of four Tfr1-
siRNA samples showed significantly reduced PrPC levels in CAD5 cells. Next, I validated the 
candidate Tfr1 using siRNA from another commercial library (Thermo Fisher Scientific). By 
PrPC-HPFRET and the cell viability assay, I confirmed that silencing Tfr1 in CAD5 cells yields 
more than a 50% PrPC reduction (Figure 6.7a).  
I predicted that silencing Tfr1 could inhibit prion replication and thus tested the hypothesis by 
infecting Tfr1-siRNA transfected CAD5 cells with prion inoculum RML6. We checked the 
PrPSc level by PrPSc-HPFRET and the cell viability assay, and were able to show that PrPSc 
replication was significantly blocked by Tfr1-siRNA treatment (Figure 6.7b).  
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Figure 6.7 Validation of Tfr1-siRNA treatment by PrPC-HPFRET and PrPSc-HPFRET. (a) CAD5 
cells were plated in a 384-well plate and transfected with Tfr1 and control siRNAs. After 72 hours, the 
cell viability assay and PrPC-HPFRET were performed to quantify PrPC protein in the cell lysate. Tfr1-
siRNA treatment significantly reduced PrPC level in both neuronal cell lines (****P<0.0001). (b) CAD5 
cells were plated in a 384-well plate and transfected with Tfr1 and control siRNAs for 24 hours, then 
exposed to RML6 for 72 hours. PrPSc-HPFRET and cell viability assay was performed to quantify 
PrPSc protein in cell lysate. Tfr1-siRNA treatment significantly blocked PrPSc replication (****P<0.0001). 
 
Furthermore, I checked the specificity of silencing Tfr1 in CAD5 cells by Western blot and 
confirmed that Tfr1 protein level was efficiently reduced by Tfr1-siRNA treatment (Figure 6.8). 
Meanwhile, PrPC protein level was significantly decreased, in accordance with the PrPC-
HPFRET results.  
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Figure 6.8 Validation of Tfr1-siRNA treatment in CAD5 cells by Western blot. CAD5 cells were 
plated in a 24-well plate and transfected with Tfr1 and control siRNAs. After 72 hours, cells were 
harvested and lysed for BCA and Western blot. (a) Tfr1 expression was efficiently silenced by Tfr1-
siRNA (****P<0.0001). (b) PrPC protein level was significantly reduced by Tfr1-siRNA treatment 
(****P<0.0001). 
 
6.5.4 Tfr1-siRNA treatment reduced the Prnp mRNA level 
To check whether the Tfr1-siRNA mediated regulation of PrPC expression occurred at the 
protein-protein interaction or transcriptional/posttranscriptional level, I checked the Prnp 
mRNA in Tfr1-siRNA transfected neuronal cells by qPCR. Interestingly, the Prnp mRNA level 
showed a significant reduction in Tfr1-siRNA treated CAD5 (Figure 6.9), suggesting that 
PrPC expression could be regulated by Tfr1-siRNA at the transcriptional or posttranscriptional 
level.  
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Figure 6.9 qPCR analysis of Prnp mRNA in Tfr1-siRNA transfected neuronal cells. CAD5 cells 
were plated in a 24-well plate and transfected with Tfr1 and control siRNAs. After 72 hours, cells were 
harvested. The total RNA was extracted from cells and reversed to cDNA for qPCR. The Prnp mRNA 
level was significantly reduced by Tfr1-siRNA treatment in CAD5 cells (****P<0.0001, *P<0.05). 
 
I also performed the Tfr1-siRNA treatment in another mouse neuronal cell line N2aPK1 
(Klohn, Stoltze et al. 2003), and confirmed the Tfr1-siRNA effect by PrPC-HPFRET and 
qPCR (Figure 6.10).  
 
Figure 6.10 Validation of Tfr1-siRNA treatment in N2aPK1 cells. (a) N2aPK1 cells were plated in a 
384-well plate and transfected with Tfr1 and control siRNAs. After 72 hours, the cell viability assay and 
PrPC-HPFRET were performed to quantify PrPC protein in the cell lysate. Tfr1-siRNA treatment 
significantly reduced the PrPC level (****P<0.0001). (b) N2aPK1 cells were plated in a 24-well plate 
and transfected with Tfr1 and control siRNAs. After 72 hours, cells were harvested. The total RNA was 
extracted from cells and reversed to cDNA for qPCR. The Prnp mRNA level in CAD5 cells was 
significantly reduced by Tfr1-siRNA treatment (*P<0.05). 
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Then, I tested the same siRNA treatment using a new cell line, hyCAD5, which expresses 
PrPC under the CMV promoter in Prnp-/- CAD5 cells. I transfected the hyCAD5 cells with Tfr1-
siRNA, 72 hours later, the PrPC level was quantified by PrPC-HPFRET. In contrast wild-type 
CAD5 cells, PrPC levels were not reduced in hyCAD5 cells after Tfr1-siRNA transfection 
(Figure 6.11). 
 
Figure 6.11 Validation of Tfr1-siRNA treatment in hyCAD5 cells. hyCAD5 cells (expressing PrPC 
under CMV promoter in Prnp-/- CAD5 cells) were plated in a 384-well plate and transfected with Tfr1 
and control siRNAs. After 72 hours, the cell viability assay and PrPC-HPFRET were performed to 
quantify PrPC protein in the cell lysate. The PrPC protein level was not reduced by Tfr1-siRNA 
treatment in hyCAD5 cells. 
 
6.5.5 Genome-wide transcriptome analysis of Tfr1-siRNA treated CAD5 by RNAseq 
To further check whether other transcriptional changes are induced by silencing Tfr1, I 
prepared total RNA from Tfr1-siRNA and nontarget-siRNA transfected CAD5 cells. I 
performed the same treatment twice. In each treatment, there were two groups of samples:  
nontarget-siRNA and Tfr1-siRNA treatment samples with four biological replicates per group. 
Then I sent total 16 samples to the Functional Genomics Center Zurich for RNAseq analysis, 
in order to compare the total RNA between Tfr1-siRNA and nontarget-siRNA treated groups. 
The RNAseq results showed that there are 1367 significant genes with a threshold p-value < 
0.01 and ≥ 2 fold-change (Figure 6.12-6.13, Table 6.1). Furthermore, the expression of 99 
genes significantly changed with a >4-fold-change and p-value < 1e-5, in which 48 genes 
were down-regulated (Table 6.2) and 51 genes upregulated (Table 6.3). In this result, Tfr1 
was the top7 and Prnp the top11 down regulated gene expression. Other interesting genes 
related to PD and AD diseases, e.g., Park2 (Parkinson disease autosomal recessive, juvenile 
2) was significantly upregulated with a 5.2 fold-change, p<1e-5, LRRK2 (leucine-rich repeat 
kinase 2, encoded by the PARK8 gene in humans) was significantly downregulated with a 
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2.7 fold-change, p<1e-5, and Mapt (microtubule-associated protein tau) was significantly 
downregulated with a 2.8 fold-change, p<1e-5. 
 
Figure 6.12 Inspection of significant genes. P-value threshold: p <= 0.01. Log ratio threshold: log 
ratio >= 1. Number of significant genes: 1367. Subsequent plots highlight significant genes in red. 
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Figure 6.13 Clustering of significant features. 
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Table 6.1 Number of significant genes according to by p-value and fold-change (fc) 
  Number of significants 
False Discovery 
Rate (FDR) 
fc >= 
1 
fc >= 
1.5 
fc >= 
2 
fc >= 
3 
fc >= 
4 
fc >= 
8 
fc >= 
10 
p < 0.1 10101 1.25E-01 10101 3883 1368 317 99 2 0 
p < 0.05 9632 6.57E-02 9632 3870 1368 317 99 2 0 
p < 0.01 8786 1.44E-02 8786 3803 1367 317 99 2 0 
p < 0.001 7784 1.63E-03 7784 3652 1347 317 99 2 0 
p < 1e-04 6994 1.81E-04 6994 3489 1301 317 99 2 0 
p < 1e-05 6366 1.98E-05 6366 3375 1253 317 99 2 0 
 
Table 6.2 Table of Top 48 genes expression significantly down-regulated with fc >= 4 
Top 
No. Gene name Gene description 
Is 
present 
Log2 
Ratio P value FDR 
1 Tm7sf2 transmembrane 7 superfamily member 2 TRUE -2.96 9.7E-25 7.1E-24 
2 Slc1a7 solute carrier family 1 (glutamate transporter), member 7 TRUE -2.75 2.6E-25 2.0E-24 
3 Fgf11 fibroblast growth factor 11 TRUE -2.51 1.9E-20 1.1E-19 
4 Sh2d6 SH2 domain containing 6 TRUE -2.51 1.1E-20 6.3E-20 
5 Aoc3 amine oxidase, copper containing 3 TRUE -2.45 6.5E-22 4.0E-21 
6 Gm3448 predicted gene 3448 TRUE -2.44 1.8E-13 6.7E-13 
7 Tfrc transferrin receptor 1 TRUE -2.42 6.0E-69 3.6E-67 
8 Mettl7b methyltransferase like 7B  TRUE -2.39 2.4E-10 7.1E-10 
9 Rad23a RAD23a homolog (S. cerevisiae)  TRUE -2.36 1.7E-60 7.0E-59 
10 2900011O08Rik RIKEN cDNA 2900011O08 gene  TRUE -2.36 6.4E-18 3.1E-17 
11 Prnp prion protein TRUE -2.35 2.1E-52 5.9E-51 
12 Tecr trans-2,3-enoyl-CoA reductase TRUE -2.35 2.0E-51 5.5E-50 
13 Pcdhgb1 protocadherin gamma subfamily B, 1 TRUE -2.35 4.8E-95 7.1E-93 
14 Kcnc3 potassium voltage gated channel, Shaw-related subfamily, member 3 TRUE -2.35 5.3E-41 8.7E-40 
15 Plekhg4 
pleckstrin homology domain 
containing, family G (with RhoGef 
domain) member 4 
TRUE -2.34 7.1E-47 1.6E-45 
16 Mst1 macrophage stimulating 1 (hepatocyte growth factor-like)  TRUE -2.34 4.3E-17 2.0E-16 
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17 Cdk10 cyclin-dependent kinase 10 TRUE -2.33 1.4E-37 2.0E-36 
18 Ttll11 tubulin tyrosine ligase-like family, member 11 TRUE -2.30 3.3E-26 2.6E-25 
19 Gnb3 guanine nucleotide binding protein (G protein), beta 3 TRUE -2.29 2.6E-31 2.6E-30 
20 Masp2 mannan-binding lectin serine peptidase 2 TRUE -2.28 1.4E-34 1.7E-33 
21 Fam132b family with sequence similarity 132, member B TRUE -2.22 1.2E-32 1.3E-31 
22 Olfml2a olfactomedin-like 2A TRUE -2.22 1.5E-56 5.1E-55 
23 Pcdha9 protocadherin alpha 9 TRUE -2.22 1.8E-33 2.1E-32 
24 Ndrg4 N-myc downstream regulated gene 4 TRUE -2.22 1.2E-26 9.8E-26 
25 Fam129c family with sequence similarity 129, member C TRUE -2.22 9.0E-17 4.1E-16 
26 Fah fumarylacetoacetate hydrolase TRUE -2.21 3.0E-59 1.2E-57 
27 Ulbp1 UL16 binding protein 1 TRUE -2.21 3.6E-16 1.6E-15 
28 Liph lipase, member H TRUE -2.20 4.3E-10 1.2E-09 
29 Tsacc TSSK6 activating co-chaperone TRUE -2.20 3.7E-17 1.7E-16 
30 Dgka diacylglycerol kinase, alpha TRUE -2.19 3.1E-48 7.4E-47 
31 Lrsam1 leucine rich repeat and sterile alpha motif containing 1 TRUE -2.14 1.1E-35 1.5E-34 
32 Flot1 flotillin 1 TRUE -2.13 2.2E-38 3.3E-37 
33 Plekhn1 pleckstrin homology domain containing, family N member 1 TRUE -2.10 5.9E-10 1.7E-09 
34 Cdk14 cyclin-dependent kinase 14 TRUE -2.08 2.5E-80 2.2E-78 
35 Tdg thymine DNA glycosylase TRUE -2.06 1.5E-56 5.1E-55 
36 Pcdha7 protocadherin alpha 7 TRUE -2.06 2.1E-33 2.4E-32 
37 Prmt2 protein arginine N-methyltransferase 2 TRUE -2.05 2.1E-23 1.4E-22 
38 Pycr1 pyrroline-5-carboxylate reductase 1 TRUE -2.04 1.0E-31 1.1E-30 
39 Inhbe inhibin beta E TRUE -2.04 1.0E-08 2.6E-08 
40 Myo7a myosin VIIA TRUE -2.03 3.6E-26 2.9E-25 
41 Myrip myosin VIIA and Rab interacting protein TRUE -2.03 5.6E-290 3.6E-286 
42 Izumo4 IZUMO family member 4 TRUE -2.03 6.6E-19 3.4E-18 
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43 Lgals4 lectin, galactose binding, soluble 4 TRUE -2.02 7.6E-12 2.5E-11 
44 Bche butyrylcholinesterase TRUE -2.01 6.8E-80 5.9E-78 
45 Mar-04 membrane-associated ring finger (C3HC4) 4 TRUE -2.01 1.4E-36 1.9E-35 
46 Parp3 poly (ADP-ribose) polymerase family, member 3 TRUE -2.01 2.5E-41 4.2E-40 
47 Lcat lecithin cholesterol acyltransferase TRUE -2.01 7.2E-17 3.3E-16 
48 Map4k1 mitogen-activated protein kinase 1 TRUE -2.00 7.9E-53 2.3E-51 
 
Table 6.3 Table of Top 51 genes expression significantly up-regulated with fc >= 4 
Top 
No. 
Gene name Gene description Is 
present 
Log2 
Ratio 
P value FDR 
1 2610524H06Rik RIKEN cDNA 2610524H06 gene TRUE 3.12 1.3E-33 1.6E-32 
2 Klhdc7a kelch domain containing 7A TRUE 3.11 1.1E-37 1.6E-36 
3 Ccdc170 coiled-coil domain containing 170 TRUE 2.98 6.0E-25 4.4E-24 
4 Rab19 RAB19, member RAS oncogene family TRUE 2.86 3.7E-14 1.4E-13 
5 Cd209c CD209c antigen TRUE 2.85 2.0E-26 1.6E-25 
6 Gm28041 predicted gene, 28041 TRUE 2.71 2.4E-13 8.5E-13 
7 Gpr4 G protein-coupled receptor 4 TRUE 2.68 8.9E-26 6.9E-25 
8 Gm10031 predicted pseudogene 10031 TRUE 2.58 2.1E-10 6.1E-10 
9 Gm20695 predicted gene 20695 TRUE 2.51 4.6E-13 1.6E-12 
10 Rgs2 regulator of G-protein signaling 2 TRUE 2.50 1.5E-21 8.9E-21 
11 Mansc1 MANSC domain containing 1 TRUE 2.46 3.3E-56 1.1E-54 
12 Cxcr2 chemokine (C-X-C motif) receptor 2 TRUE 2.44 5.3E-89 6.3E-87 
13 Foxr1 forkhead box R1 TRUE 2.43 2.2E-22 1.4E-21 
14 Trim12c tripartite motif-containing 12C TRUE 2.42 1.8E-45 3.7E-44 
15 Pbld2 phenazine biosynthesis-like protein domain containing 2 TRUE 2.39 7.4E-123 2.2E-120 
16 Park2 Parkinson disease (autosomal recessive, juvenile) 2 TRUE 2.38 7.7E-82 7.5E-80 
17 Enkur enkurin, TRPC channel interacting protein TRUE 2.37 1.6E-50 4.4E-49 
18 Adck3 aarF domain containing kinase 3 TRUE 2.36 9.5E-115 2.4E-112 
19 Ccrl2 chemokine (C-C motif) receptor-like TRUE 2.35 2.3E-16 1.0E-15 
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2 
20 Xaf1 XIAP associated factor 1 TRUE 2.34 4.1E-44 7.9E-43 
21 Nlrc3 NLR family, CARD domain containing 3 TRUE 2.32 3.0E-109 6.5E-107 
22 Pld6 phospholipase D family, member 6 TRUE 2.30 1.1E-12 3.9E-12 
23 Grxcr2 glutaredoxin, cysteine rich 2 TRUE 2.30 7.2E-15 2.9E-14 
24 C730034F03Rik RIKEN cDNA C730034F03 gene TRUE 2.30 5.6E-68 3.2E-66 
25 Trim72 tripartite motif-containing 72 TRUE 2.27 9.1E-18 4.4E-17 
26 Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 TRUE 2.24 5.7E-17 2.6E-16 
27 Upk1b uroplakin 1B TRUE 2.23 2.6E-17 1.2E-16 
28 1500015O10Rik RIKEN cDNA 1500015O10 gene TRUE 2.23 1.7E-13 6.3E-13 
29 Slamf1 signaling lymphocytic activation molecule family member 1 TRUE 2.21 1.3E-131 4.6E-129 
30 Ccdc62 coiled-coil domain containing 62 TRUE 2.20 1.6E-105 3.2E-103 
31 Edaradd EDAR (ectodysplasin-A receptor)-associated death domain TRUE 2.20 1.7E-10 5.0E-10 
32 Mmp17 matrix metallopeptidase 17 TRUE 2.20 4.8E-35 6.0E-34 
33 Lrriq1 leucine-rich repeats and IQ motif containing 1 TRUE 2.20 1.4E-16 6.2E-16 
34 Zfp819 zinc finger protein 819 TRUE 2.19 2.3E-19 1.2E-18 
35 1700001P01Rik RIKEN cDNA 1700001P01 gene TRUE 2.16 3.4E-34 4.1E-33 
36 Thbs4 thrombospondin 4 TRUE 2.15 1.3E-85 1.3E-83 
37 Dmbx1 diencephalon/mesencephalon homeobox 1 TRUE 2.14 4.0E-24 2.9E-23 
38 Lrrc34 leucine rich repeat containing 34 TRUE 2.13 1.8E-12 6.0E-12 
39 Myl9 myosin, light polypeptide 9, regulatory TRUE 2.13 1.4E-26 1.1E-25 
40 Per2 period circadian clock 2 TRUE 2.11 6.7E-235 1.4E-231 
41 Zfp791 zinc finger protein 791 TRUE 2.06 3.3E-19 1.8E-18 
42 Aqp8 aquaporin 8 TRUE 2.04 5.4E-11 1.6E-10 
43 Hacd4 3-hydroxyacyl-CoA dehydratase 4 TRUE 2.03 1.7E-45 3.5E-44 
44 Igtp interferon gamma induced GTPase TRUE 2.02 3.1E-51 8.5E-50 
45 Cx3cl1 chemokine (C-X3-C motif) ligand 1 TRUE 2.02 8.7E-28 7.5E-27 
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46 Cpne1 copine I TRUE 2.02 1.1E-17 5.2E-17 
47 Fam46b family with sequence similarity 46, member B TRUE 2.02 1.9E-14 7.5E-14 
48 Tc2n tandem C2 domains, nuclear TRUE 2.02 3.7E-13 1.3E-12 
49 Nipal1 NIPA-like domain containing 1 TRUE 2.02 2.4E-07 5.4E-07 
50 Grb10 growth factor receptor bound protein 
10 
TRUE 2.00 4.4E-42 7.6E-41 
51 Spef1 sperm flagellar 1 TRUE 2.00 1.9E-67 1.0E-65 
 
6.5.6 Regulation of PrPC expression by iron treatment in cell culture 
Because Tfr1 was discovered to be involved in PrPC expression, I wanted to regulate PrPC 
expression by altering the Tfr1 level in cell culture. First, we down regulated Tfr1 in neuronal 
cells by adding ferric iron supplement. CAD5 cells were treated with ferric ammonium citrate 
(FAC, formula is (NH4)5Fe(C6H4O7)2) for 48 hours in a 384-well plate, then PrPC protein levels 
were checked by PrPC-HPFRET, cell viability assay (Figure 6.14a). I further validated the 
same treatment in a 24-well plate. Cells were harvested and lysed for BCA, then PrPC and 
Tfr1 protein levels in cell lysate were checked by western blot (Figure 6.14b). The FAC 
treatment reduced PrPC protein level in a concentration dependent manner. The 250 μg/mL 
FAC already yielded 20% Tfr1 reduction and more than 50% PrPC reduction.  
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Figure 6.14 Treatment of ferric ammonium citrate in cell culture. (a) CAD5 cells were plated in a 
384-well plate and treated with ferric ammonium citrate (FAC) for 48 hours. Then cell viability assay 
and PrPC-HPFRET were performed to quantify PrPC. The FAC treatment reduced PrPC in a 
concentration dependent manner. The 250 μg/mL FAC treatment significantly reduced PrPC by more 
than 50% (****P<0.0001).  (b) CAD5 cells were plated in a 24-well plate and treated with FAC for 48 
hours. Then cells were harvested and lysed for BCA and Western blot. The 250 μg/mL FAC yielded a 
20% Tfr1 reduction and a more than 50% PrPC reduction (***P<0.001).  
 
Next, I did ferric iron chelator treatment in CAD5 cells. The CAD5 cells were treated with iron 
chelator deferoxamine mesylate (DFO) for 48 hours, the PrPC and Tfr1 protein levels were 
checked by PrPC-HPFRET, cell viability assay (Figure 6.15a) and western blot (Figure 
6.15b). DFO treatment increased PrPC level in a concentration dependent manner and the 
15 μg/mL DFO induced significant increase of Tfr1 and PrPC.  
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Figure 6.15 Treatment of deferoxamine mesylate in cell culture. (a) The CAD5 cells were plated in 
a 384-well plate and treated with deferoxamine mesylate (DFO) for 48 hours. Then the cell viability 
assay and PrPC-HPFRET were performed to quantify PrPC. The DFO treatment increased PrPC in a 
concentration dependent manner. The 15 μg/mL DFO treatment significantly increased PrPC 
(****P<0.0001).  (b) CAD5 cells were plated in a 24-well plate and treated DFO for 48 hours. Then 
cells were harvested and lysed for BCA and Western blot. The 15 μg/mL DFO significant increased 
Tfr1 and PrPC (*P<0.05). 
 
6.5.7 Inhibition of PrPSc replication by iron treatment in cell culture 
Because 250 μg/mL FAC reduced PrPC expression by more than 50%, I wanted to inhibit 
PrPSc replication by FAC treatment in prion infected CAD5 cells. First, I tested FAC treatment 
before prion infection. CAD5 cells were treated with 250 μg/mL FAC for 24 hours in a 384-
well plate and then infected with 0.1% RML6 BH. 72 hours later, PrPSc protein levels were 
checked by PrPSc-HPFRET, cell viability assay (Figure 6.15 a-b). The 250 μg/mL FAC 
treatment before prion infection efficiently and remarkably blocked PrPSc replication (Figure 
6.15c). Next, I tested FAC treatment after prion infection. CAD5 cells were incubated with 0.1% 
RML6 BH for 24 hours and then treated with 250 μg/mL FAC. 72 hours later, PrPSc protein 
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levels were checked by PrPSc-HPFRET, cell viability assay (Figure 6.15 d-e). The 250 μg/mL 
FAC treatment after prion infection significantly reduced PrPSc replication (Figure 6.15f). 
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Figure 6.16 Treatment with ferric ammonium citrate before or after prion infection in cell culture. 
(a-c) CAD5 cells were plated in a 384-well plate, treated with 250 μg/mL ferric ammonium citrate (FAC) 
for 24 hours and then infected with 0.1% RML6 BH. After 72 hours’ incubation, cell viability assay and 
PrPSc-HPFRET were performed to quantify PrPSc. The FAC treatment before prion infection efficiently 
and significantly reduced PrPSc replication (****P<0.0001).  (e-f) CAD5 cells were plated in a 384-well 
plate, infected with 0.1% RML6 BH for 24 hours and then treated with 250 μg/mL ferric ammonium 
citrate (FAC). After 72 hours’ incubation, cell viability assay and PrPSc-HPFRET were performed to 
quantify PrPSc. The FAC treatment after prion infection significantly reduced PrPSc replication 
(****P<0.0001).   
 
6.5.8 Regulation of PrPC expression by iron treatment in mouse model 
To explore the potential of iron supplement for prion therapy, I performed the following in vivo 
experiments. 1) The wild-type C57BL/6 mice were fed an iron deficient diet for three weeks. 
The preliminary result showed that PrPC levels in brains were significantly increased in the 
iron deficient diet mice compared to the normal diet mice (Figure 6.17a). 2) The 
intraperitoneal (i.p.) injection of ferri carboxymaltosum (ferinject® from Vifor) into wild-type 
C57BL/6 mice. The iron injection was performed three times per week for 4 weeks with, and 
then PrPC expression level in mouse brain was checked by PrPC-HPFRET (Figure 6.17b) 
and Western blot (Figure 6.17c). PrPC protein levels in brains were significantly reduced in 
iron injected mice compared to PBS injected mice. 
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Figure 6.17 Regulation of PrPC expression in mouse brains by iron treatment. (a) Wild-type 
C57BL/6 mice were fed an iron deficient diet for three weeks. Control group mice were fed normal diet. 
The PrPC proteins in brain homogenate were detected by PrPC-HPFRET. PrPC levels in the iron 
deficient diet mouse brains were significantly increased compared to the normal diet mice (**P<0.01). 
(b-c) Wild-type C57BL/6 mice were intraperitoneal (i.p.) injected with ferri carboxymaltosum (ferinject® 
from Vifor) for 4 weeks with three times per week. PrPC expression level in mouse brain was checked 
by PrPC-HPFRET and Western blot. PrPC protein levels in brains were significantly reduced in ferri 
carboxymaltosum injected mice compared to PBS injected mice (*P<0.05, **P<0.01). 
 
6.6 Discussion 
Recent research has revealed novel functions of the endocytic membrane system, implying 
that endocytosis could be a master organizer of signalling circuits that resolve signals in 
space and time for cellular communication and interactions with the environment, not only for 
the internalization of nutrients and membrane associated molecules (Scita and Di Fiore 2010, 
Liberali, Snijder et al. 2014). However, endocytic RNAi HTS and the relevant systematic 
analysis have not been achieved in prion research. For the first part of my thesis, I 
established PrPC-HPFRET and PrPSc-HPFRET, which are highly adapted to automated high-
throughput screening platforms for basic and applied prion research. Specifically, this 
technique facilitates high-throughput screening for the identification of chemicals interfering 
with prion secretion, prion infection, and/or prion replication, and genome-wide RNAi or 
CRISPR/Cas9 screens aimed at understanding the molecular mechanisms of prion 
transmissibility and replication. Therefore, for the second part of my thesis, I combined the 
newly developed PrP-HPFRET assays with RNAi HTS technologies to identify genes 
regulating endogenous cellular prion protein expression. In addition, I established an 
automated PrP-HPFRET based high-throughput siRNA screening platform and screened 
3153 mouse siRNAs targeting 780 genes that are involved in endocytic membrane trafficking 
pathways.  
From the siRNA HTS of endocytosis genes, I found an interesting candidate gene, Tfr1, that 
silences Tfr1 efficiently, repressing endogenous PrPC expression through transcriptional or 
post-transcriptional regulation, and thus blocks PrPSc replication in neuronal cells. The well-
known function of Tfr1, a homodimeric type II transmembrane glycoprotein, is involved in iron 
uptake and cell growth regulation (Neckers and Trepel 1986). A Tfr1 protein can internalize 
up to four ferric ions during one cycle of Tfr1-mediated endocytosis, which has been recently 
characterized as a useful target for cancer therapy (Daniels, Delgado et al. 2006, Tortorella 
and Karagiannis 2014). In my experiments, iron treatment in cell culture model confirmed 
that altering Tfr1 level can affect PrPC expression in neuronal cells, suggesting that Tfr1 
could be a novel therapeutic target to supress cellular prion protein for prion diseases. 
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6.7 Outlook 
To better understand the role of endocytosis-relevant genes on prion protein expression, 
additional data analysis will continue over the next several months. The raw screening data 
is still under analysis by our collaborating bioinformaticians for off-targeting analysis, the 
functional interaction networks and pathways analysis, druggable candidate genes as well as 
database mining for available compounds. Afterwards, any interesting druggable genes 
(besides Tfr1) will be validated and relevant compounds will be tested by in vitro and in vivo 
models.  
To further understand the mechanism of Tfr1 on PrPC expression, our collaborating 
bioinformaticians will continue to analyze RNAseq data from the Tfr1-siRNA transfected 
CAD5 cells. Ninety-nine significant expression changes with >4-fold-change, p<1e-5 were 
identified. Interestingly, the expression levels of selected important genes related to 
neurodegenerative diseases were significantly changed by Tfr1-siRNA treatment. For 
example, the Park2 (Parkinson disease autosomal recessive, juvenile 2) gene expression 
was significantly up regulated with a 5.2-fold-change, p<1e-5, the Mapt (microtubule-
associated protein tau) was significantly downregulated with a 2.8-fold-change, p<1e-5. 
Therefore, I hope that we will find highly related clusters and pathways based on the RNAseq 
data, which could provide us with additional insight to guide later studies. 
To explore the potential of iron supplement for prion therapy,  some in vivo experiments have 
been carried out: 1) Preliminary results showed that PrPC expression was significantly 
reduced in the brains of C57BL/6 mice, which were fed an iron-deficient diet for three weeks, 
compared to the normal diet mice. 2) Another experiment involved was intraperitoneal (i.p.) 
injection of ferri carboxymaltosum (ferinject® from Vifor) into wild-type C57BL/6 mice for 
assessment of PrPC expression in the brains. The results showed that the PrPC expression 
was remarkably reduced in the brains of wild-type C57BL/6 mice i.p. injected with ferri 
carboxymaltosum, Therefore, we propose to treat chronically prion-infected mice with iron, to 
determine whether the incubation time of prion disease is prolonged. 
 
6.8 Material and Methods 
6.8.1 Chemicals and tissue homogenate 
Chemicals for buffers were purchased from Sigma-Aldrich. Mouse brain tissue was 
homogenized in 0.32 M sucrose (or PBS) to 10% (w/v, 100 mg of tissue per 900 µl 
homogenization buffer) and stored at -80°C. The protein concentration was determined using 
the bicinchoninic acid assay (Pierce). 
 
6.8.2 Mouse prion susceptible neuronal cell line 
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Mouse cell line CAD-2A2D5 (CAD5) cells were derived from Cath.a-differentiated cells 
(Mahal, Baker et al. 2007). Mouse cell line N2aPK1(Klohn, Stoltze et al. 2003) was a 
subclone of the neuroblastoma cell line (N2a).  
 
6.8.3 Murine siRNA screen 
1) Murine siRNA library 
An arrayed murine siRNA library in 96-well plates was provided by the Novartis Institute for 
BioMedical Research. The siRNA samples were reformatted from 96-well source plates into 
384-well source plates that were specifically used for making siRNA stamps on the Labcyte 
Echo acoustic liquid handling platform. Then siRNA controls were dispensed using the “Plate 
Reformat” program and siRNA samples were dispensed using the “Cherry Pick” program 
with sample picking lists (Figure 6.18). The assay plates were stored in a -40°C freezer. 
The sequence of the control Prnp-siRNA (from ambion by life technologies, siRNA ID # 
s72188) is: 5´-CGUGAAAACAUGUACCGCUtt-3´. The control nontarget-siRNA was 
purchased from Ambion by Life Technologies as well: Select Negative Control No. 1 siRNA, 
catalog number is 4390844. 
 
Chapter 6 
RESULTS PART II: Establishment of an automated PrP-HPFRET 
based high-throughput siRNA screening platform. 
 
77 
 
 
Chapter 6 
RESULTS PART II: Establishment of an automated PrP-HPFRET 
based high-throughput siRNA screening platform. 
 
78 
 
Figure 6.18 Making siRNA stamps in 384-well plates by Labcyte Echo acoustic liquid handling 
platform. (a) siRNA controls were dispensed using the “Plate Reformat” program. (b)  siRNA samples 
were dispensed using the “Cherry Pick” program with sample picking lists. 
 
2) siRNA transfection in CAD5 cells 
The siRNA stamps were thawed to room temperature. Plates were centrifuged at 2000rpm x 
1min. The transfection mix was prepared according to Lipofectamine® RNAiMAX Reagent 
Protocol. 4ul of transfection mix was dispensed into each well. Plates were centrifuged at 
2000rpm x 1min incubated at room temperature for 10 minutes. Cells were harvested when 
TPP Tissue Culture (T300) flasks were 80% confluent. A cell suspension was made at the 
desired density in an assay medium that contained the CAD5 cell suspension at 2800 
cells/15 μl/well in Opti-MEM® I Reduced-Serum Medium (no phenol red) plus 10% FBS 
(HyClone). 15 μl of cell suspension was dispensed into each well containing siRNA and the 
transfection mix. Plates were incubated at 37°C and 5% CO2 for 24 hrs. Then 20 μl of 0.5x 
Realtime-Glo (Promega, catalog number is G9713) in OFBS medium was dispensed into 
each well. Plates were incubated at 37°C and 5% CO2 for 48 hrs. 
 
3) Cell viability assay and PrPC-HPFRET assays 
72 hours after adding Realtime-Glo, plates were taken out from incubator and the Realtime-
Glo luminescence in each well was detected by Envision Multilabel Reader. The RealTime-
Glo™ cell viability assay determines the number of viable cells in culture by measuring the 
reducing potential of cells and thus metabolism. The assay involves adding NanoLuc® 
luciferase and a cell-permeant prosubstrate, the cell viability substrate, to cells in culture. 
Viable cells reduce the proprietary prosubstrate to generate a substrate for NanoLuc 
luciferase. This substrate diffuses from cells into the surrounding culture medium, where it is 
rapidly used by the NanoLuc enzyme to produce a luminescent signal. The signal correlates 
with the number of viable cells. Both the cell viability substrate and NanoLuc enzyme are 
stable in complete cell culture medium at 37°C for at least 72 hours. No cell washing, 
removal of medium or further reagent addition is required to determine the number of viable 
cells. 
Immediately after reading the Realtime-Glo, PrPC-HPFRET was performed in 384-well plates 
with the following steps: 1) cell lysis: 10 µl/well of 5x standard lysis buffer was dispensed in 
each well without medium removal. The final concentration in each well was 1x standard 
lysis buffer. The plate was shaken at 37°C for 10 min at 700 rpm. 2) FRET antibody pair 
incubation: FRET antibody pair Eu2+-POM19 and APC-POM1 stock was diluted with 1x 
Lance buffer to 30 nM (concentration of POM antibody) and 60 nM (concentration of POM 
antibody). 5 µl/well of 30 nM Eu2+-POM19 and 5 µl/well of 60nM APC-POM1 were added 
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separately. The plate was shaken at 37°C for 1 h at 300 rpm. 3) The DPICA plate’s clear 
bottom was sealed with white BackSeal-384 (PerkinElmer) for the top read of time-resolved 
FRET. The FRET signal of PrPC in each well was detected by EnVision Multilabel Reader. 
 
Table 6.4 Overview of protocols for the PrPC screen 
  Reagent Experiment volume 
Working 
conc. Tool 
siRNA 
 printing
Control siRNA 2 ul/well 60 nM Echo 
Seal plates, store plates in -40°C -40°C freezer 
 Day 1
OptiMEM 4 ul/well  Biotek MultiFlo FX  
(Peristaltic pump) 
1 µL 
cassette 
Lipofectamine RNAiMAX 1 ul/well  
1 µL 
cassette 
For siRNA-lipid mixture formation: 1 min centrifugation at 
2000rpm, incubate 10 min at RT  Plate centrifuge 
WT CAD5 cells 15 ul/well 2800 cells/well 
Biotek MultiFlo FX  
(Peristaltic pump) 
5 µL 
cassette 
KO CAD5 cells 15 ul/well 2800 cells/well 5 µL cassette 
 Day 2 RT-Glo medium (P/S) 20 ul/well 0.25 x 5 µL cassette 
48h incubation  Cell culture incubator 
 Day 4
      Read RT-Glo luminecence Envision 
5x lysis buffer 10 ul/well 1x Biotek MultiFlo FX  (Peristaltic pump) 
5 µL 
cassette 
Seal plates, 700 rpm shaking 15min at RT  multiple-plates shaker 
Eu2+-POM19 5 ul/well 2.5 nM 
Biotek MultiFlo FX  
(Peristaltic pump) 
1 µL 
cassette 
APC-POM1 5 ul/well 5 nM 1 µL cassette 
Seal plates, 700 rpm shaking 1h at 37°C  multiple-plates shaker 
      Read FRET Envision Multilabel Reader 
 
6.8.4 Screen data analysis 
The screening raw data was analyzed by collaborating bioinformaticians (Prof. Ioannis 
Xenarios' lab, University of Lausanne) for the quality control reports, off-targeting analysis, 
hits selection and network pathway analysis. 
 
6.8.5 RNA sequencing 
Total RNA was isolated from cultured CAD5 cells using the RNeasy mini kit (QIAGEN). RNA 
quality was analyzed by Bioanalyzer 2100 (Agilent Technologies). RNAs with RIN>9 were 
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used to prepare library for the polyA-selected approach. The TruSeq RNA Sample Prep kit 
v2 (Illumina) was used in the following steps. In brief, total RNA samples (1 µg) were poly A 
enriched and reverse transcribed into double-stranded cDNA. TruSeq adapters were ligated 
to double-stranded cDNA. Fragments containing TruSeq adapters on both ends were 
selectively enriched with PCR. Quality and the quantity of enriched libraries was validated 
using Qubit (1.0) Fluorometer and Caliper GX LabChip GX (Caliper Life Sciences). The 
product was a smear with a mean fragment size of ∼260 bp. Libraries were normalized to 10 
nM in Tris-Cl 10 mM, pH 8.5, with 0.1% (vol/vol) Tween 20. 
TruSeq PE Cluster kit v4-cBot-HS (Illumina) was used for cluster generation using 2 pM of 
pooled normalized libraries on the cBOT. Sequencing was performed on Illumina HiSeq 2500 
at 1 × 100 bp using the TruSeq SBS kit v4-HS (Illumina). Reads were quality-checked using 
FastQC. 
 
6.8.6 qRT-PCR.  
Total RNA from each brain was extracted using RNeasy mini Kit (QIAGEN). The quality of 
RNA was analyzed by Bioanalyzer 2100 (Agilent Technologies), RNAs with RIN>7 were 
used for cDNA synthesis. cDNA were synthesized from ~1 μg total RNA using QuantiTect 
Reverse Transcription kit (QIAGEN) according to the manufacturer’s instruction. Quantitative 
real-time PCR (qRT-PCR) was performed using the SYBR Green PCR Master Mix (Roche) 
on a ViiA7 Real-Time PCR system (Applied Biosystems). Expression levels were normalized 
using Gapdh. The sequence of qRT-PCR primers are as follows: Gapdh sense, 5´-CCA CCC 
CAG CAA GGA GAC T-3´; antisense, 5´-GAA ATT GTG AGG GAG ATG CT-3´. Prnp sense, 
5´-GCC AGT GGA TCA GTA CAG CA-3´; antisense, 5´-ATC CCA CGA TCA GGA AGA TG-
3´. Tfr1 sense, 5´-CAT GAG GGA AAT CAA TGA TCG TA-3´; antisense, 5´-GCC CCA GAA 
GAT ATG TCG GAA-3´.  
 
6.8.7 Western blot analysis 
To detect PrPC, cells were washed once with PBS and lysed with RIPPA buffer. The cell 
lysate was centrifuged at 14000g for 20min at 4°C. The supernatant was removed. The total 
protein concentration was determined using the bicinchoninic acid assay (Pierce). 
Approximately 15 μg of proteins were loaded and separated on a 12% Bis-Tris 
polyacrylamide gel (NuPAGE; Invitrogen, Waltham, MA, USA) and then blotted onto a 
nitrocellulose membrane. Membranes were blocked with 5% wt/vol Topblock (Sigma-Aldrich, 
Fluka, 37766, manufactured by Juro AG, Lucerne, Switzerland) in PBS supplemented with 
0.05% Tween 20 (vol/vol) and incubated with primary antibodies POM1 in 1% Topblock (200 
ng mL−1) overnight. After washing, the membranes were incubated with a secondary 
antibody horseradish peroxidase (HRP)-conjugated rabbit anti–mouse IgG1 (1:10,000, 
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Zymed). Blots were developed using Luminata Crescendo Western HRP substrate (Millipore, 
Billerica, MA, USA) was visualized using the Stella system (model 3000, Bio-Rad). To avoid 
variation in loading, the same blots were striped and incubated with an anti-actin antibody 
(1:10,000, Millipore). The PrPC signals were normalized to actin as a loading control.  
To detect Tfr1 in cell lysate, approximately 15 μg of proteins were loaded and separated on a 
12% Bis-Tris polyacrylamide gel (NuPAGE; Invitrogen, Waltham, MA, USA) and then blotted 
onto a nitrocellulose membrane. Membranes were blocked with 5% wt/vol Topblock (Sigma-
Aldrich, Fluka, 37766, manufactured by Juro AG, Lucerne, Switzerland) in PBS 
supplemented with 0.05% Tween 20 (vol/vol) and incubated with primary antibodies Tfr1 
(1:1,000, Invitrogen) in 1% Topblock overnight. After washing, the membranes were then 
incubated with secondary antibody horseradish peroxidase (HRP)-conjugated goat anti–
mouse IgG1 (1:5,000, Jackson ImmunoResearch). Blots were developed using Luminata 
Crescendo Western HRP substrate (Millipore, Billerica, MA, USA) and visualized using the 
Stella system (model 3000, Bio-Rad). To avoid the variation in loading, the same blots were 
striped and incubated with an anti-actin antibody (1:10,000, Millipore). The Tfr1 signals were 
normalized to actin as a loading control. 
 
6.8.8 Iron treatment in neuronal cells 
CAD5 cells were harvested when TPP Tissue Culture (T150) flasks were 80% confluent. A 
cell suspension was made at the desired density in OFBS medium. Ammonium iron (III) 
citrate (sigma, F5879-100G) or deferoxamine mesylate salt (Sigma, D9533-1G) was diluted 
to the desired concentration with OFBS medium and added to the plates. Plates were 
incubated at 37°C and 5% CO2 for 48 hrs. For the 384-well plates, the cell viability assay and 
PrPC-HPFRET were performed to quantify PrPC. For 24-well plates, the cells were harvested 
from the plates and lysed for BCA and Western blot analysis of the total proteins in the cell 
lysate. 
 
6.8.9 Iron treatment before or after prion infection in neuronal cells 
CAD5 cells were harvested when TPP Tissue Culture (T150) flasks were 80% confluent. A 
cell suspension was made at the desired density in OFBS medium, 1000 cells/well cells or 
were added into 384-well plates. CAD5 Prnp-/- cells were used as negative controls. 
For iron treatment before prion infection: 1) Ammonium iron (III) citrate (sigma, F5879-100G) 
was diluted to the desired concentration (end conc. was 250 μg/mL) with OFBS medium and 
added to the plates, and plates were incubated at 37°C and 5% CO2 for 24 hrs;  2) RML6 BH 
was diluted to the desired concentration (end conc. was 0.1%) with OFBS medium and 
added to the plates, and plates were incubated at 37°C and 5% CO2 for 24 hrs; 3) Realtime-
Glo was diluted to the desired concentration (end conc. was 0.25x) with OFBS medium and 
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added to the plates, and plates were incubated at 37°C and 5% CO2 for 48 hrs; 4) The cell 
viability assay and PrPSc-HPFRET were performed to quantify PrPSc. 
For iron treatment after prion infection: 1) RML6 BH was diluted to the desired concentration 
(end conc. was 0.1%) with OFBS medium and added to the plates, and plates were 
incubated at 37°C and 5% CO2 for 24 hrs; 2) Ammonium iron (III) citrate (sigma, F5879-100G) 
was diluted to the desired concentration (end conc. was 250 μg/mL) with OFBS medium and 
added to the plates, and plates were incubated at 37°C and 5% CO2 for 24 hrs; 3) Realtime-
Glo was diluted to the desired concentration (end conc. was 0.25x) with OFBS medium and 
added to the plates, and plates were incubated at 37°C and 5% CO2 for 48 hrs; 4) the cell 
viability assay and PrPSc-HPFRET were performed to quantify PrPSc. 
 
6.8.10 Iron treatment in mice 
Wild-type C57BL/6 mice were fed an iron deficient diet for three weeks. Control group mice 
were fed normal diet. Then brains were collected from mice and homogenized in 0.32M 
sucrose. The total protein in BH was measured by BCA and then PrPC proteins in BH were 
detected by PrPC-HPFRET.  
Wild-type C57BL/6 mice were intraperitoneal (i.p.) injected with ferri carboxymaltosum 
(ferinject® from Vifor). The injection dose was 500μg/g body weight. Control group mice were 
injected by PBS. The injection was performed totally 4 weeks with three times per week. 
Then brains were collected from mice and homogenized in 0.32M sucrose. The total protein 
in BH was measured by BCA and then PrPC proteins in BH were detected by PrPC-HPFRET 
and Western blot. 
 
6.8.11 Statistical analysis.  
Results are presented as the mean of replicas ± standard error of the mean (SEM). 
Statistical significance between experimental groups was assessed using an unpaired 
Student’s t-Test or two-way analysis of variance (ANOVA). p-values <0.05 were considered 
statistically significant. 
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